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Objective:  The proposed study will examine the association between the dipeptidyl 
peptidase-4 inhibitors (DPP-4i) drug class and the risk of major adverse cardiovascular 
events (MACE) in patients with diabetes.   
 
Methods:  In the surveillance portion of this dissertation, we utilized the Food and Drug 
Administration’s Adverse Events Reporting System (FAERS) to conduct a Bayesian 
disproportionality analysis on reports for MACE associated with DPP-4i, to assess the 
association of DPP-4i with a cardiovascular subset of reports to the full database.  These 
associations were quantified using the posterior distribution of the empirical Bayes lower 
bound (EB05) of the relative reporting ratio, among high- and low- risk populations.  
Next for the longitudinal analyses, we conducted retrospective, time to first MACE 
analyses of data from Truven Marketscan Commercial Claims and Encounters to 
compare new users of DPP-4i versus sulfonylurea and DPP-4i versus metformin.  This 
association was measured using propensity score weighted Cox proportional hazards 
models, adjusted for baseline demographics, comorbidities, and concomitant medications.  
Propensity score weights, based on baseline clinical characteristics and concomitant 
medications, were calculated using a generalized boosted logistic regression model.  This 
analysis was repeated in both individuals with established cardiovascular and/or kidney 
disease (high-risk cohort), as well as in individuals without these medical conditions 
(low-risk cohort).  
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Results: In the surveillance study, there was a safety signal for heart failure with 
linagliptin (EB05=2,782.47) and saxagliptin (EB05=2.40), myocardial infarction with 
alogliptin (EB05=290.11), and cerebral infarction with sitagliptin (EB05=2.80) in the 
cardiovascular subset of reports.  Eight of fourteen possible MACE events had a percent 
positive agreement ≥50% for a drug-event safety signal in both the cardiovascular subset 
and the full dataset.  Overall, the cardiovascular subset elicited 11 more safety signals for 
DPP-4i than the full dataset.  In the longitudinal analysis of low-risk individuals, DPP-4i 
use was associated with lower risk for MACE than sulfonylurea use (adjusted Hazard 
Ratio (aHR)=0.87; 95% Confidence Interval (CI): [0.78, 0.98]), and no increased risk for 
MACE compared to metformin use (aHR=1.07; 95% CI: [0.97, 1.18]).  Risk for acute 
myocardial infarction (aHR=0.70; 95% CI: [0.51, 0.96]), stroke (aHR=0.57; 95%CI: 
[0.41, 0.79]), and heart failure (aHR=0.57; 95% CI: 0.41, 0.79) with DPP-4i was lower 
compared to sulfonylureas.  In the longitudinal analysis of high-risk individuals, DPP-4i 
was associated with lower risk for MACE than sulfonylurea (aHR=0.84; 95% CI: [0.7, 
0.9]), and with no increased risk for MACE compared to metformin (aHR=1.07; 95% CI: 
[1.0, 1.2]).   
 
Conclusions: This dissertation confirms the evidence that DPP-4i carry less risk for 
MACE compared to sulfonylureas in new users of antihyperglycemic therapy for type 2 
diabetes.  Additionally, DPP-4i and metformin are similar in risk of MACE.  While the 
surveillance data showed a signal for heart failure with some DPP-4i, further prospective 
analyses of longitudinal data did not lead to evidence to support the drug label warning 
for increased risk of heart failure among high-risk patients with the use of DPP-4i. 
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Type 2 diabetes mellitus (T2DM) is a common and costly disease, affecting nearly 
1/3 of the United States population and often presenting with many comorbidities, 
including cardiovascular disease1.  Patients with T2DM can be treated with 
antihyperglycemic agents spanning nine drug classes, each with their respective risks and 
benefits.  While these therapies allow patients to manage blood glucose levels, some 
come with side effects such as hypoglycemia or gastrointestinal upset.  The United States 
Food and Drug Administration (FDA) has approved 15 dipeptidyl peptidase-4 inhibitors 
(DPP-4i) since 2006. This class of drug was thought to protect against acute 
cardiovascular events, making them a safer option to rosiglitazone and other 
thiazolidinediones, after a link between rosiglitazone and myocardial infarction was 
identified in 20072.   
In February 2014, the FDA issued a Drug Safety Communication regarding increased 
risk of congestive heart failure (CHF) with the DPP-4i saxagliptin in response to the 
publication of results from the Saxagliptin Assessment of Vascular Outcomes Recorded 
in Patients with Diabetes Mellitus (SAVOR) trial3,4.  While SAVOR investigators 
collected baseline data on cardiovascular risk, it was limited to age and having one of 
three risk factors (hyperlipidemia, hypertension, or active smoking).  Re-analysis of 
results suggested an increased risk of CHF compared to placebo; however, the trial was 
designed to assess CHF as part of a composite, secondary outcome4.  As such, FDA 
convened an Advisory Committee to assess the data for increased risk of CHF with 
saxagliptin and look at data from the Examination of Cardiovascular Outcomes with 
Alogliptin versus Standard of Care (EXAMINE) trial for alogliptin, which was conducted 
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in patients with acute coronary syndrome.  Data regarding the co-primary endpoint of 
death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke, 
showed no increased risk associated with alogliptin use5.  While the Advisory Committee 
recognized the dangers of making post-hoc assessments on trial data, the re-analysis of 
both trials showed a non-statistically significant increased risk for CHF with DPP-4i use.  
FDA erred on the side of caution and placed a warning of generalized cardiovascular risk 
on the saxagliptin and alogliptin labels.  
DPP-4i’s are among the most common treatments for T2DM and many patients have 
comorbid cardiovascular diseases such as hypertension and hyperlipidemia.  Data from 
SAVOR and EXAMINE do not suggest statistically significant increases in 
cardiovascular risk for these products, yet signal detection through spontaneous reports 
indicate that cardiovascular risk should be evaluated in a systematic manner for this class 
of drug6.  With this discrepancy in mind, we used post-marketing adverse event and 
commercial claims data to assess whether safety concerns exhibited through spontaneous 
reporting are indicative of increased hazards of acute cardiovascular events and death 
among patients who have taken DPP-4i compared to those on sulfonylureas and 
metformin.   
 
Specific Aim 1: To determine whether post-marketing surveillance of DPP-4i elicit a 
safety signal for an increased risk of acute cardiovascular events compared to 
sulfonylureas and metformin in (1) the full set of drug-related adverse event reports and 
(2) in a subset of adverse event reports consisting of all FDA-approved cardiovascular 
and diabetic drug products.  
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Hypothesis 1.1: There will be a safety signal for major adverse cardiovascular events 
associated with each DPP-4i drug in the full set of drug-related adverse event reports.  
Hypothesis 1.2: There will be a safety signal for major adverse cardiovascular events 
associated with each DPP-4i drug in the subset of reports from cardiovascular and 
diabetic products.   
 
Specific Aim 2: To compare the hazards of acute cardiovascular events or death with the 
use of DPP-4i versus sulfonylureas and metformin among treatment naïve patients 
without prior cardiovascular disease or renal impairment using commercial claims data.  
Hypothesis 2.1: The hazard of acute cardiovascular events in individuals without 
cardiovascular disease or renal impairment is greater with DPP-4i than with 
sulfonylureas and metformin.  
 
Specific Aim 3: To assess whether the hazards of acute cardiovascular events or death 
differ with the use of DPP-4i versus sulfonylureas and metformin among treatment naïve 
patients with prior cardiovascular disease and/or renal impairment using commercial 
claims data.  
Hypothesis 3.1: The hazard of acute cardiovascular events in individuals with 
cardiovascular disease and/or renal impairment is greater with DPP-4i than with 
sulfonylureas and metformin. 
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 Type 2 diabetes mellitus (T2DM) is a common and chronic disease in the United 
States.  The United States Centers for Disease Control and Prevention estimates that 
9.4% of the United States population currently have diabetes1.  This often presents with a 
host of comorbidities, including cardiovascular disease.  In the following dissertation, we 
first provide a comprehensive review of the epidemiology of diabetes in the United 
States.  Next, we consider the United States Food and Drug Administration (FDA) 
approved pharmacological treatment options for T2DM and the cardiovascular safety 
concerns with these products.  Finally, we discuss the current evidence base and 
regulatory framework for assessing the cardiovascular safety of dipeptidyl peptidase-4 
inhibitors (DPP-4i), one class of oral antihyperglycemic agents.   
 Following this overview, we present three papers that provide empiric 
examinations of the association between DPP-4i and cardiovascular events. In the first 
manuscript, we evaluate the relationship between DPP-4i and major adverse 
cardiovascular events spontaneously reported to the FDA Adverse Event Reporting 
System (FAERS).  We assessed the presence of safety signals in both the full set of 
adverse event reports and a subset of reports for drugs indicated for cardiovascular and 
diabetic indications.  This approach allowed us to determine whether there was 
disproportional reporting of major adverse cardiovascular events for DPP-4i overall and 
within the context of drugs commonly prescribed to diabetic patients at high risk for 
experiencing a major adverse cardiovascular event.  
 In the second manuscript, we used commercial claims data to investigate the 
association between DPP-4i use and major adverse cardiovascular events among patients 
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without a history of cardiovascular disease. We compare this association to that of 
sulfonylureas and metformin.  By controlling for risk factors such as hypertension and 
hypercholesterolemia through surrogate markers of medications used to treat those 
conditions, we could better assess whether or not the risk of major adverse cardiovascular 
events were due to DPP-4i use or underlying cardiovascular disease.   
 In the third manuscript, we conducted a similar analysis in patients with a history 
of major adverse cardiovascular events and/or renal impairment (i.e. chronic kidney 
disease and acute kidney impairment).  This group was identified by FDA in a 2008 
Guidance for Industry as a vulnerable population, whose cardiovascular risk with the use 
of oral antihyperglycemic agents is poorly understood2.  The clinical trial data regarding 
cardiovascular safety of DPP-4i submitted to FDA suggested that a prior history of 
cardiovascular disease and/or renal impairment modified the relationship between DPP-4i 
and major adverse cardiovascular events when compared to those without this medical 
history.  By analyzing this cohort separately, we were able to investigate the association 
between DPP-4i use and major adverse cardiovascular events in this subgroup of interest. 
 Finally, we conclude with the implications of our findings in light of current 
evidence on the cardiovascular safety of DPP-4i.  We discuss the potential impact on 




Diabetes is common among patients with cardiovascular disease. 
The CDC estimates that 30.3 million people suffer from diabetes in the United 
States, and 90-95% of these cases are T2DM patients3.  Additionally an estimated 86 
million Americans over age 20 are pre-diabetic4.  This statistic becomes especially 
concerning in light of data showing that diabetes often presents with cardiovascular 
disease (CVD)5.  These two diseases are often preceded by a cluster of symptoms 
commonly referred to as metabolic syndrome, which comprises of any three of the 
following five conditions: elevated fasting blood glucose, elevated waist circumference, 
elevated triglycerides, reduced HDL-C, and elevated blood pressure.  Metabolic 
syndrome increases the risk of developing diabetes by five-fold; additionally, it increases 
the risk of CVD in the following 5-10 years by 50%6.  Further complicating this 
relationship, diabetes often increases individual risk for cardiovascular disease7.  An 
estimated 71% of diabetic patients over age 18 either have blood pressure greater than or 
equal to 140/90 mmHg or are currently taking antihypertensive medication4.  
 
There are many treatment options for patients with T2DM 
Before physicians and patients pursue pharmaceutical therapies for T2DM, 
patients are often asked to make lifestyle modifications such as increased exercise and 
reduced dietary sugar and carbohydrate intake.  When these actions show minimal or no 
effect on glycemic control, patients with T2DM can be treated with any combination of 
antihyperglycemic agents from nine classes, namely sulfonylureas, biguanides, 
meglitinides, thiazolidinediones, sodium/glucose cotransporter 2 (SLGT2) inhibitors, 
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alpha-glucosidase inhibitors, GLP-1 agonists, bile acid sequestrants, and DPP-4i.  The 
American Academy of Clinical Endocrinologists recently released their prescribing 
algorithm for antihyperglycemic agents8.  These agents are often prescribed in a step-
wise fashion.  Among mono-therapy options are metformin, DPP-4i, and sulfonylureas.  
As patients progress with the disease, dual-therapy can be initiated when HbA1c levels 
are ≥7.5%, and triple-therapy with the option for insulin treatment can be used when this 
is no longer effective.  As T2DM is a metabolic disorder affecting insulin action and 
secretion, each of these drug classes works by either indirectly regulating the amount of 
glucose or the amount of insulin released into the blood.  
 
Table 1. Drug Classes of Antihyperglycemic Agents for the Treatment of Type 2 
Diabetes Mellitus 
Treatment Class Mechanism of Action Example Side Effect(s) 
Sulfonylureas Stimulate pancreas to release more 
insulin 
Hypoglycemia 
Biguanides Decrease glucose produced in liver Diarrhea 
Meglitinides Stimulate pancreas to release more 
insulin 
Hypoglycemia 
Thiazolidinediones Assist insulin effectiveness in muscle 
and fat; reduce glucose production in 
liver 
Heart failure 
DPP-4 Inhibitors Prevent breakdown of GLP-1 Upper respiratory tract 
infection 





Blocks breakdown of starches in 
intestine 
Gas and diarrhea 
GLP-1 agonists Prevent breakdown of GLP-1 Acute pancreatitis 
Bile acid 
sequestrants 







Many antihyperglycemic agents associated with cardiovascular events 
On May 21, 2007 the FDA issued a Boxed Warning for Avandia (rosiglitazone), a 
thiazolidinedione, for a possible increased risk for myocardial infarctions.  This warning 
was based on both an internal and external meta-analysis examining the association 
between rosiglitazone and myocardial infarction and death from cardiovascular events9.  
The trials included in these meta-analyses were small and primarily placebo-controlled; 
however, many were not powered or designed to detect cardiovascular events.  At the 
time of the Nissen and Wolski review, the Rosiglitazone Evaluated for Cardiac Outcomes 
and Regulation of Glycemia in Diabetes (RECORD) trial was ongoing; later results 
would suggest an increased risk for heart failure but no increased risk for overall 
cardiovascular morbidity or mortality when compared to metformin and sulfonylurea10.  
The Avandia label was updated in August 2007 to include a warning that the drug might 
cause or exacerbate heart failure in some patients.  Additionally, rosiglitazone was 
contraindicated for those with a prior history of the New York Heart Association class III 
or IV heart failure.   
Over the next four years, FDA expanded the Risk Evaluation and Mitigation 
Strategies program for rosiglitazone containing products by restricting access to patients 
who were already successfully treated with these medications and those whose blood 
sugar could not be controlled with other anti-diabetic medications and did not wish to use 
pioglitazone-containing products.  The data from RECORD was re-evaluated in 2011.  At 
this time, possible bias was uncovered due to misclassification of cardiovascular events.  
The re-evaluation showed that there was no increased risk for heart attacks compared to 
metformin and sulfonylurea.  Despite the eventual removal of these prescribing 
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restrictions, these actions prompted the development of a Guidance for Industry on 
evaluating cardiovascular risk with T2DM therapies and increased vigilance for 
cardiovascular events upon the approval of subsequent antihyperglycemic agents2.   
 
Association between DPP-4i and acute cardiovascular events remains unclear 
One of the more recent classes of antihyperglycemic agents to be approved is DPP-4i.   
These treatments act by preventing the breakdown of glucogon-like peptide-1 (GLP-1)11.  
The breakdown of GLP-1 stimulates the release of insulin, improving glucose 
homeostasis.  DPP-4i carry a low risk of hypoglycemia and are not associated with 
weight gain or gastrointestinal symptoms that are often commonly found with the use of 
other antihyperglycemic agents.  Additionally, DPP-4i were initially thought to protect 
against major adverse cardiac events (MACE), making them a safer option to 
rosiglitazone and other thiazolidinediones, which have been linked to heart failure9,12.   
FDA issued a Drug Safety Communication in 2014 for generalized cardiovascular 
risk with the use of these products based on Saxagliptin Assessment of Vascular 
Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR), a placebo-controlled, 
phase 4 trial investigating cardiovascular risk with saxagliptin, and post-marketing 
surveillance data for saxagliptin, alogliptin, and sitagliptin13,14.  Similar to the case of 
rosiglitazone, the weight of evidence supporting the Drug Safety Communication did not 
definitively point to an increased risk of cardiovascular events with the use of saxagliptin.  
Baseline data on cardiovascular risk for SAVOR showed that all patients either had 
multiple risk factors for cardiovascular disease or were diagnosed with cardiovascular 
disease15.  Results suggested an increased risk of heart failure compared to placebo, but 
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SAVOR was only designed to assess heart failure as part of a composite, secondary 
outcome14.  Common drawbacks of composite outcomes include interpreting the 
significance of results when they are not uniform across all components of the composite 
outcome16.  In this case, interpreting the risk of one component of the composite could 
lead to possible type I error.  Additionally, the composite outcome was a secondary 
outcome, calling into question its validity and reproducibility17. 
The Endocrinologic and Metabolic Drugs Advisory Committee also assessed the 
Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care 
(EXAMINE) data for cardiovascular events associated with alogliptin.  In contrast to 
SAVOR, EXAMINE was conducted in patients with acute coronary syndrome.  Of the 
5380 patients, 77.2% had previously suffered a myocardial infarction, and the remainder 
22.6% had unstable angina18.  These post-hoc analyses were assessed with due caution, 
especially since heart failure and other acute cardiovascular events are rare.  Both trials 
showed a non-statistically significant increased risk for congestive heart failure with 
DPP-4i use in high-risk populations.  However, out of an abundance of caution, FDA 
placed a warning of generalized cardiovascular risk on the labels of saxagliptin and 
alogliptin products. Noting that deaths from CVD are two- to eight-fold higher in T2DM 
patients, the drug label warnings on DPP-4i provide proactive protection for at-risk 
patients; however, these actions might inadvertently limit treatment options for patients 
when the evidence for their claims are less than conclusive.   
Recently published data from the Trial Evaluating Cardiovascular Outcomes with 
Sitagliptin (TECOS) trial, which evaluated the primary composite outcome of 
cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization 
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for unstable angina in patients >50 years old with established CVD, showed that 
sitagliptin was noninferior compared to placebo (HR=0.98, 95% CI: 0.83, 1.20, 
P=0.98)19.  In addition to the TECOS trial, recent observational data from Taiwan’s 
National Health Insurance Research Database also support no increased risk of acute 
cardiovascular events with the use of DPP-4i.  DPP-4i treated patients were matched to 
non-DPP-4i treated patients on clinical and socio-demographic characteristics and 
followed for all-cause mortality (HR=0.79, 95% CI: 0.72, 0.87) and major adverse 
cardiovascular event (HR=0.79, 95%CI: 0.75, 0.83)20.  While these studies suggest no 
increased risk for acute cardiovascular events, they were designed to assess composite 
outcomes.  The benefit of spontaneously reported adverse events reports is their ability to 
detect specific, rare event signals without having to tease out composite outcomes.   
 
Data Sources 
FDA Adverse Event Reporting System 
FDA currently collects adverse event reports for all of its regulated products 
through MedWatch, a passive adverse event surveillance system developed in 1993.  This 
portal collects reports from patients, patient advocates, and providers.  Additionally, 
manufacturers are required to submit spontaneously reported adverse event reports for 
their products within 15-days of receipt of the information by the applicant.  Reports 
from both of these pathways are organized and entered into the FDA Adverse Events 
Reporting System (FAERS).  This information was initially used to detect drug-event 
combinations in patients taking more than one product, since clinical trials submitted 
during the drug-approval process typically exclude these types of patients.  Over time, the 
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system has evolved to collect information on the adverse event (date, duration, related 
laboratory test results), drug (manufacturer, dose, frequency, duration of treatment, route 
of administration, prescribed indication), patient background (age, sex, weight, 
concomitant medications), and event abatement upon dechallenge and rechallenge of 
suspect medication.  Case reports are available free-of-charge and downloadable as 
FAERS Quarterly Data Files, via web access on the FDA website.  FDA relies heavily on 
FAERS to detect safety issues in a larger, heterogeneous patient population21.   
 
Truven Health Analytics MarketScan® Commercial Claims and Encounters Database 
MarketScan Commercial Claims and Encounters Database (Commercial) contains 
linked medical and drug data for millions of Americans covered by approximately 350 
payors.  The data are representative of insured employees and their families, early 
retirees, Consolidated Omnibus Budget Reconciliation Act covered users, and Medicare 
Supplemental insurance holders.  Insurance plans include fully- and partially-capitated 
fee-for-service, preferred provider organizations, exclusive provider organizations, point 
of service plans, indemnity plans, health maintenance organizations, and consumer-
directed health plans.  Employer database data consist of inpatient cases, inpatient 
services, outpatient services, capitated encounter records, enrollment counts, and 
outpatient prescription drug claims.  There are currently data on 210 million unique 
patients in the database, spanning all 50 states since 1995.  MarketScan is particularly 






This dissertation focused on the association between DPP-4i and major adverse 
cardiovascular events.  In order to understand this association, we first assessed safety 
signals in the FAERS reports submitted to FDA to better understand whether the drug-
event combination of DPP-4i therapy and major adverse cardiovascular events was 
greater than would be expected given the background risk in the full set of adverse event 
reports and in a subset of reports consisting of all adverse events reported for 
cardiovascular and diabetic drug products (AIM 1).  Next, we examined the medical 
history of treatment naïve patients without a history of cardiovascular disease or renal 
impairment to assess whether the risk for major adverse cardiovascular events is 
increased with the use of DPP-4i compared to sulfonylureas and to metformin using a 
propensity score weighted Cox proportional hazard model, adjusting for individual 
demographics, comorbidities, and concomitant medications (AIM 2).  Finally, we 
conducted a similar analysis in treatment naïve patients with a history of cardiovascular 
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Purpose: In 2008, the U.S. Food and Drug Administration (FDA) issued Draft Guidance 
on investigating cardiovascular risk with oral diabetic drugs, including dipeptidyl 
peptidase-4 inhibitors (DPP-4i).  In 2014, underpowered, post-hoc analyses of clinical 
trials suggested an increased risk of heart failure with the use of these products.  As such, 
we assessed disproportionate reporting of major adverse cardiac events (MACE) among 
reports for DPP-4i submitted to the FDA Adverse Event Reporting System (FAERS) 
from 2006-2015.   
 
Methods. We assessed the empirical Bayes geometric mean (EBGM) and its lower 
bound (EB05) of the relative reporting ratio for MACE among DPP-4i reports in the full 
FAERS database and in a subset of reports limited to cardiovascular and diabetic drugs.  
We then compared the EB05 in these two analyses and calculated the percent positive 
agreement for signals of disproportional reporting (SDR) involving MACE.   
 
Results.  Of 180.3 million adverse event reports, 13.4 million were for diabetic and 
cardiovascular drugs.  In the cardiovascular subset, there was a SDR for heart failure with 
linagliptin (EB05=2782.47) and saxagliptin (EB05=2.40), myocardial infarction with 
alogliptin (EB05=290.11), and cerebral infarction with sitagliptin (EB05=2.80).  Of the 
14 MACE, 8 had a percent positive agreement ≥50% for a SDR in both analyses.  




Conclusions.  Postmarketing surveillance of DPP-4i through FAERS suggest increased 
reporting of MACE, supporting the current FDA warning of heart failure risk.  This 
suggests the need for additional longitudinal, observational research into the association 
of DPP-4i and other MACE.   
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As of 2015, the Centers for Disease Control and Prevention estimate that 23.1 
million people in the United States have diagnosed diabetes, 5% of whom have type 1 
diabetes8.  Many of these patients also experience medical complications such as 
coronary heart disease, stroke, nephropathy, neuropathy and retinopathy23. Following the 
approval of many new classes of medications, the mean number of diabetic medications 
prescribed per patient visit was 1.45 in 2007, an increase of 0.39 from 199424.  These 
treatments have a variety of novel mechanisms targeting the pancreas, liver, kidney, 
gastrointestinal tract, or muscle and fat tissues.  While there are a variety of treatment 
options available, both providers and regulators seek to better understand the benefits and 
risks of these medications in postmarket settings.   
Among the newest medicines, glitazones, incretins, and dipeptidyl peptidase-4 
inhibitors (DPP-4i) have increased in market share since their introduction in 200325.  
Since the approval of the first DPP-4i, sitagliptin, in 2006, the U.S. Food and Drug 
Administration (FDA) have approved ten additional single-ingredient or fixed-dosed 
combination DPP-4i.  These treatments are approved as monotherapy as well as add-on 
therapy to metformin and act by preventing the breakdown of glucogon-like peptide-1 
(GLP-1)15.  The breakdown of GLP-1 stimulates the release of insulin, improving glucose 
homeostasis.  DPP-4i have several appealing characteristics including a low risk of 
hypoglycemia as well as the absence of an association with weight gain or 
gastrointestinal symptoms that often limit the use of other anti-diabetic products.  Based 
on premarketing clinical trial data, adverse events are less severe than other treatment 
options but include acute pancreatitis26.  In addition, DPP-4i were initially thought to 
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protect against major adverse cardiac events (MACE), making them a safer option to 
rosiglitazone and other thiazolidinediones, which have been linked to heart failure1,16.  
However, while failing to reach statistical significance, one Phase 4 trial suggested 
hospitalization for heart failure with saxagliptin use3.   
Given continued interest in the cardiovascular safety of these products on the part 
of patients, clinicians, payers and regulators, we compared signals for disproportional 
reporting (SDR) for MACE for DPP-4i in the full set of drug-related FDA adverse event 
reports and a subset containing all of the adverse event reports for cardiovascular and 





We used post-marketing adverse event data submitted to the FDA Adverse Events 
Reporting System (FAERS) to assess whether safety concerns exhibited through 
spontaneous reporting were suggestive of an association between DPP-4i use and MACE.  
We accessed FAERS reports submitted to the FDA from October 1, 2006 to December 
31, 2015 via the FAERS Quarterly Data Files published online by the FDA27.  This time 
period captured adverse events submitted to FDA from October 16, 2006, when 
sitagliptin, the first DPP-4i, was approved.  We then filtered the reports for FDA drug 
products using the list of brand and generic drugs in the FDA publication, Approved 
Drug Products with Therapeutic Equivalent Evaluations in order to include all FDA 
approved drug products and exclude other FDA approved products such as biologics28.  
We excluded reports without a suspect medication (N=3,556), adverse event (N=0) or 
 
 25 
report number (N=0).  Each drug-event combination in FAERS is listed as individual 
records and linked via report number.  From these reports, we abstracted the report 
number, patient age, patient sex, suspect drug, concomitant medications, adverse event, 
and date of report.  
 
Rationale of Datasets and Analytic Approach  
We conducted Bayesian disproportionality analyses using two different sets of 
data. We use the full set of drug-related adverse event reports in FAERS (“full set”) and a 
subset of reports submitted only for non-insulin antihyperglycemic agents and drugs 
indicated for cardiovascular disease (“cardiovascular subset”).  By using these two 
different sets, we were able to compare and contrast SDR between two datasets with 
different assumptions regarding the Bayesian prior for the disproportionality analysis.  In 
the overall body of FAERS reports, the Bayesian prior comprised of the general patient 
population and therefore assumed average risk for MACE.  In the cardiovascular subset, 
the Bayesian prior assumed a higher risk for the patient population in that they were 
known to have diabetes or cardiovascular disease by virtue of the drugs they were on.  In 
each dataset, we also compared the EB05 for DPP-4i to those of sulfonylureas and 
biguanides.  We compared the results of DPP-4i with sulfonylureas due to their known 
cardiovascular risk29, high utilization, and similar patient population to DPP-4i patients.  
We chose biguanides as a second comparison group due to their relatively low 





We first characterized the patients for whom adverse event reports were submitted 
for DPP-4i, sulfonylureas, and biguanides in both the full set and cardiovascular subset.   
We conducted disproportionality analyses on every drug-event combination in the 
full dataset to determine the Empirical Bayes geometric mean of the relative reporting 
ratio (EBGM).  We used the DuMouchel multi-item gamma Poisson shrinkage method to 
derive and rank the EBGM31.  The method allows for the comparison of reporting ratios 
of individual adverse events for a particular drug and the full database of adverse events.  
In this analysis, the full database serves as the Bayesian prior.  This method has been 
extensively replicated for the use of data-mining in pharmacovigilance32-35. The EBGM 
allowed for valid assessments of relative reporting ratios even in the presence of small 
samples within the database.  From these EBGMs we took the lower bound on the 90% 
credible interval to establish a threshold consistent with FDA practice of EB05 >2.0 to 
indicate a SDR for any drug-event combination36.  Events were pre-coded with the latest 
version of preferred terms from the Medical Dictionary for Regulatory Activities 
(MedDRA) dictionary at the time of release in the FAERS quarterly data file.  From the 
full list of SDR, we focused on the results pertaining to MACE.  We defined major 
adverse cardiovascular events as any of the following MedDRA terms: acute myocardial 
infarction, atrioventricular block complete, cardiogenic shock, myocardial infarction, 
arteriosclerosis coronary artery, cardiac arrest, cardiac failure, cardiac failure congestive, 
sudden death, sudden cardiac death, cerebrovascular event, cerebral infarction, 
hemorrhagic stroke, and ischemic stroke.   
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For our cardiovascular subset of reports, we filtered the full dataset for all reports 
for suspect drugs that were FDA approved oral antihyperglycemic agents or 
cardiovascular medications listed in Supplemental Table 1.  From the cardiovascular 
subset, we conducted the DuMouchel disproportionality analysis on each drug-event 
combination to determine the EB05.  In this analysis, the oral antihyperglycemic agents 
and cardiovascular drugs served as the Bayesian prior.  We then assessed the percent 
positive agreement for the signals for MACE between the cardiovascular subset and the 
full set of reports.   
Finally, we compared the disproportionality results of MACE reporting for DPP-
4i, sulfonylureas, and biguanides for the cardiovascular set and the full set of reports.  We 
also calculated the percent positive agreement between signals for MACE with DPP-4i, 
sulfonylureas, and biguanides in the full dataset and the cardiovascular subset.   
In order to determine whether or not reporting of MACE was sensitive to 
regulatory actions related to oral antihyperglycemic agents, we assessed the possibility of 
stimulated reporting of adverse events with DPP-4i using the methods previously 
described by Hoffman et al37.  We first identified three actions that could have potentially 
stimulated the reporting of adverse events with oral antihyperglycemic agents: the 2007 
FDA warning about cardiovascular risk with the use of rosiglitazone-containing products, 
the 2008 FDA Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular 
Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, and the 2014 FDA warning 
regarding the risk of congestive heart failure with the use of DPP-4i1,2,7,38.  To assess 
whether these actions resulted in an increase in reporting, we then compared the period 
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after these actions to the period after sham actions.  We chose sham action dates five 
fiscal quarters prior to the regulatory actions.   
For each of the regulatory actions and sham actions, we calculated the percent 
change in the number of reports in the two quarters after the regulatory and sham actions 
and performed a Mann-Whitney test to assess statistically significant differences in 
percent change between the pairs.  






There were a total of 180.4 million drug-event pairs in the full dataset and 13.4 
million (7.4%) in the cardiovascular subset.  208,385 (0.1%) reports were for DPP-4i 
from patients with a median of 60 (IQR: 56, 71) years of age.  Of reports associated with 
DPP-4i, the majority (51.8%) was from male patients, 37.1% listed concomitant 
medications, and 43.4% were attributed to a sitagliptin-containing product. 
A total of 444,780 reports were for sulfonylureas.  Of these, three-fifths involved 
males, the median patient age was 63 (IQR: 53, 73) years, 77.6% listed concomitant 
medications, and glimepiride was most commonly represented (59.0%).  Additionally, 
345,580 reports were for biguanides, involving patients with a median age of 62 (IQR: 
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53, 70) years of whom approximately one-half (51.5%) were male and 60.1% listed 
concomitant medications.   
Full FAERS Dataset 
For myocardial infarction, there was a signal with alogliptin (EB05=15.9) among 
the DPP-4i.  Among the sulfonylureas and biguanides, chlorpropamide (EB05=27.9), 
glipizide (EB05=2.8), glipizide extended release (EB05=2.1), and metformin 
hydrochloride (EB05=6.7) elicited SDR for myocardial infarction.  For cerebral 
infarction, there was one DPP-4i SDR with sitagliptin (EB05=2.5).  With the 
sulfonylureas and biguanides, glimepiride (EB05=4.0) elicited a SDR for cerebral 
infarction.  
Among the DPP-4i FAERS reports in this dataset, sitagliptin (EB05=0.5) and 
sitagliptin combined with metformin (EB05=0.4) had reports of congestive heart failure; 
however, these did not cross the threshold for a potential SDR.  In contrast, the following 
sulfonylurea-containing products elicited a SDR for congestive heart failure: glimepiride 
(EB05=2.4), glimepiride with pioglitazone hydrochloride (EB05=2.4), glimepiride with 
rosiglitazone maleate (EB05=7.3), glipizide (EB05=4.8), glyburide (EB05=3.3), and 
glyburide with metformin hydrochloride (EB05=2.7) (eTable 2, 3, 4).   
 
Report Subset with Diabetes and Cardiovascular Drugs 
Similar to the full dataset, the subset of reports from cardiovascular drugs had a 
signal for myocardial infarction with alogliptin (EB05=4.5), saxagliptin (EB05=10.0), 
chlorpropamide (EB05=13.4), glipizide (EB05=2.01), glipizide extended release 
(EB05=17.6), and metformin hydrochloride (EB05=3.2).  For cerebral infarction, there 
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was a signal with sitagliptin (EB05=2.8) and none among the sulfonylureas and 
biguanides.  Also in this subset, there was no statistically significant signal for congestive 
heart failure with any DPP-4i or biguanide.  However, the following sulfonylurea-
containing products elicited a signal for congestive heart failure: glipizide (EB05=23.7), 
and glimepiride and rosiglitazone maleate (EB05=2.4).  The DPP-4i, linagliptin 
(EB05=2782.5) and saxagliptin (EB05=2.4) elicited signals for heart failure 
(Supplemental Tables eTable 2, 3, 4).   
 
Comparison of SDR by Dataset 
There were 2 signals for MACE in the Bayesian disproportionality analysis of the 
full dataset compared to 12 with the cardiovascular subset among DPP-4i (Table 1).  
Overall among the three antihyperglycemic drug classes, there was general agreement in 
SDR between the two datasets for acute myocardial infarction and hemorrhagic stroke.  
However, there were 12 instances where the full dataset elicited a SDR, and the 
cardiovascular subset did not.  There were 12 instances where the cardiovascular subset 
elicited a SDR, and the full dataset did not.  All of the discordances in DPP-4i signals 
between the two datasets showed a signal in the cardiovascular subset but not in the full 
dataset.  However, for the sulfonylureas 11 of the 12 signal discrepancies showed a signal 







Percent Positive Agreement Between Full Set and Cardiovascular Set 
Table 2 shows the percent positive agreement between the full dataset and the 
cardiovascular subset for DPP-4i, sulfonylureas and biguanides, respectively.  Of the 14 
MACE of interest, 5 had a percent positive agreement ≥50%, suggesting that surveillance 
for a subset of reports from patients who may be at heightened risk of MACE has utility 
in detecting additional SDR. Among the reports from patients who may be expected to 
experience MACE, there was greater detection of congestive heart failure, 
atrioventricular block complete, cerebrovascular accident, and cerebral infarction.  The 
lowest percent positive agreement was with arteriosclerosis coronary artery, sudden 
death, and cerebrovascular accident each with 0% percent positive agreement.  Heart 
failure (PPA=33.3%) and congestive heart failure (PPA=33.3%) each had low percent 
positive agreement.  The analyses of the full dataset and the cardiovascular subset each 
detected 12 unique SDR.   
 
Stimulated Reporting 
Comparing the percent change between the two months after the regulatory events 
and two months after the sham events showed no statistically significant results for the 
2007 rosiglitazone warning about cardiovascular risk (W=54.0, p=0.5), the 2008 FDA 
Guidance for Industry (W=41.0, p=1.0), or the 2014 FDA warning for DPP-4i risk of 







In this disproportionality analysis of FDA adverse event reports, we examined the 
relative reporting ratio for MACE with the use of DPP-4i.  Among a subset of adverse 
events reports that are generated from a group of patients with a high risk for 
cardiovascular events, there was an increase in reporting of MACE for sitagliptin, 
saxagliptin, linagliptin, and alogliptin.  These SDR suggest that even among a group of 
reports where one would expect to see high numbers of reports for these events, the DPP-
4i class stands out.  In addition to the previously reported association with heart failure, 
our results suggest that DPP-4i adverse event reporting is increased for multiple MACE.  
Finally, we found that creating a subset of reports from drugs associated with diabetes 
and cardiovascular disease allowed for detection of additional MACE reporting.  
Interestingly, our analyses of the cardiovascular risks of DPP-4i using the full 
FAERS dataset only identified two SDR, whereas our use of the cardiovascular subset 
elicited 12 distinct signals.  By contrast, we identified fewer cardiovascular signals using 
the full rather than the subset when examining sulfonylureas (20 vs 10) and biguanides (8 
vs. 9).  This suggests that for products where there is a known association with 
cardiovascular events with those products (i.e. sulfonylureas), signal detection in the full 
FAERS dataset is sensitive enough to detect potential SDR.  However, for products 
where association is tenuous, a subset with reports from a high-risk patient population 
may be more sensitive to capture additional SDR for further investigation.   
As the purpose of disproportionality analyses is hypothesis generation, this 
evidence cannot independently support FDA actions.  While prior evidence suggested 
that DPP-4i were associated with heart failure, we were interested in investigating 
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whether or not there were additional SDR for other MACE with distinct pathogenesis 
(e.g., myocardial infarction).  In examining percent positive agreement between analyses 
of the two datasets, the cardiovascular subset can allow for greater sensitivity to detect 
SDR associations that might be confounded by comorbidities commonly found with 
diabetes.  This methodology of subsetting the adverse event reports to a high-risk pool of 
patients has utility in identifying SDR for further investigation.   
Our approach of honing in on a subset of adverse events reports from similar 
drugs or a high-risk population provides opportunities for increasing the sensitivity of 
Bayesian signal detection.  Given that signal detection methods are primarily utilized by 
regulatory agencies for hypothesis generation about drug safety issues, increasing 
sensitivity is desirable especially in cases where comorbidities may act like confounders.  
In this example, we were able to highlight additional MACE aside from heart failure that 
could be further investigated in longitudinal studies.  This method allows for increased 
vigilance for specific risk groups without the high resource allocation an FDA Risk 
Evaluation and Mitigation Strategies (REMS) program would require.   
The FDA has acknowledged the limitations of its current signal detection methods 
and is actively seeking novel approaches to its surveillance activities.  Two points of 
concern with current practices are the threshold of EB05=2.0 and residual confounding39.  
Through restriction of the Bayesian prior to adverse event reports stemming from a pool 
of patients with related illnesses, our approach can reduce the level of residual 
confounding.  Additionally, as the EB05=2.0 threshold is considered a minimal threshold 
for further investigation of a drug safety concern, regulators can adjust this threshold 
based on the restricted patient population and their unique health concerns.  For instance, 
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if this analysis approach were applied to a subset of reports associated with oncology 
products, regulators might increase the threshold for action on a non-life-threatening 
adverse event. 
Our study had several limitations.  The FAERS dataset is primarily a case report 
dataset initially developed to detect drug-drug interactions40.  In this study, we were 
mining the data for single-drug adverse event associations. Despite previously established 
low cardiovascular risk, 8 of the 14 MedDRA terms elicited SDR for biguanides, our 
negative control.  Causality remains unclear without further investigation, because the 
majority (60.1%) of the biguanide reports listed concomitant medications.  Nonetheless, 
our use of negative and positive controls provides additional context when comparing the 
results between the full set and cardiovascular subset for DPP-4i.   
Second, the level of missing covariates in the FAERS dataset did not allow for 
extensive analysis of the potential effect of demographic and medical characteristics that 
could affect the association between DPP-4i and MACE.  Additionally potential 
underreporting in the FAERS system does not capture the true number of adverse events 
in the general population.  Finally, DPP-4i are currently recommended as a first line 
diabetic therapy and are commonly prescribed to patients with more advanced diabetes 
than those on metformin or sulfonylureas15.  While this raises a concern for selection 
bias, alternative comparators such as thiazolidinediones are associated with 
cardiovascular risk14, while others such as SGLT2 inhibitors are associated with 






We found evidence to suggest further investigation of MACE SDR associated 
with DPP-4i.  While the analysis of the full dataset suggests a possible increase in 
reporting of MACE with the use of DPP-4i, the results from the cardiovascular subset 
show utility in identifying additional SDR.  This novel approach to pharmacovigilance 
contrasts with the current approach of conducting surveillance on the entire exposed 
population, irrespective of risk level.  Conducting signal detection in subsets of reports 
stemming from high-risk populations allows regulators to hone in on the most vulnerable 
members of the exposed population. Longitudinal, observational research is needed to 
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Table 1: Bayesian signals of disproportional reporting (EB05† <2.0) for antidiabetic agents in full dataset and cardiovascular subset ‡ 

EB05 <2.0  EB05 ≥2.0 
† EB05: 90% lower bound of the empirical Bayes geometric mean of the relative reporting ratio   
‡ Excludes products with n=0 reports, EB05 <0, or EBGM <0  
 
































































DPP-4 Inhibitors                             
 
alogliptin u1.34 u0.68         u15.89 u4.48         u0.16 u0.03 
 
linagliptin                     u0.29 u0.28   u3126.03 
 
saxagliptin               u9.98   u81.01   u7.17   u2.41 
 
sitagliptin u1.65 u0.81     u0.93 u0.52 u0.95 u0.46 u0.90 u0.39 u0.46 u0.71 u0.16 u1.01 
 
sitagliptin; 
metformin             u0.26 u0.05     u0.16 u0.13     
 
sitagliptin; 
metformin ER u0.45 u0.14                         
Sulfonylureas                             
 
chlorpropamide             u27.94 u13.41             
 








maleate                             
 
glipizide u139.18 u33.46 u0.79   u1.71 u3.34 u2.75 u2.01 u0.98 u0.07 u0.73 u0.45 u0.28 u0.22 
 
glipizide ER u0.45 u0.21         u36.59 u17.55     u0.26 u0.21     
 
glyburide u1.13 u0.55 u7.66 u2.50 u1.04 u0.58 u1.34 u0.65 u0.90 u0.39 u1.95 u1.67 u0.27 u0.90 
 
glyburide; 
metformin HCL u0.91 u0.46 u0.19 u0.48 u4.57 u2.58 u2.09 u1.03     u44.11 u38.48 u0.43 u0.31 
Biguanides                             
 
metformin HCL u0.58 u0.28 u12.70 u4.15 u4.06 u2.25 u6.71 u3.22 u0.59 u0.25 u0.24 u0.24 u16.12 u6.45 
 
metformin HCL 




Table 1 (cont’d): Bayesian signals of disproportional reporting (EB05† <2.0) for antidiabetic agents in full dataset and cardiovascular 
subset ‡ 

EB05 <2.0  EB05 ≥2.0 
† EB05: 90% lower bound of the empirical Bayes geometric mean of the relative reporting ratio   
‡ Excludes products with n=0 reports, EB05 <0, or EBGM <0 
    
Cardiac Failure 

































































DPP-4 Inhibitors                             
 
alogliptin     u1.97 u3.57       u606.37 u0.26 u0.07         
 
linagliptin             u0.33 u0.31             
 
saxagliptin   u0.97   u30.99   u98.70   u3.15   u0.38       u14.04 
 
sitagliptin u0.51 u0.28 u0.10 u0.06     u1.45 u0.74 u2.47 u2.81 u0.25 u0.12 u0.13 u0.04 
 
sitagliptin; 
metformin u0.43 u0.23 u0.15 u0.06     u0.06 u0.01             
 
sitagliptin; 
metformin ER             u0.34 u0.80             
Sulfonylureas                              
 
chlorpropamide                             
 








maleate u7.28 u2.38         u3.16 u1.77             
 
glipizide u4.79 u23.67 u0.39       u0.77 u0.46 u0.14   u0.67   u0.49   
 
glipizide ER u1.65 u0.92         u0.52 u0.26             
 
glyburide u3.29 u1.79 u0.54 u0.42     u1.82 u0.93 u1.72 u1.94     u0.75 u0.35 
 
glyburide; 
metformin HCL u2.66 u1.48         u1.38 u0.73 u0.12 u0.08         
Biguanides                             
 
metformin HCL u1.20 u0.65 u1.54 u2.26 u62.94 u18.14 u2.68 u1.37 u0.60 u0.67 u5.04 u2.81 u87.66 u27.52 
 
metformin HCL 




Table 2. Percent positive agreement between datasets† 
























SDR Acute myocardial infarction 1 0 100.0% 
 
Atrioventricular block complete 2 0 66.7% 
 
Cardiogenic shock 2 1 66.7% 
 
Myocardial infarction 5 1 71.4% 
 
Arteriosclerosis coronary artery 0 1 0.0% 
 
Cardiac arrest 1 1 50.0% 
 
Cardiac failure 1 2 33.3% 
 
Cardiac failure congestive 2 0 33.3% 
 
Sudden death 0 3 0.0% 
 
Sudden cardiac death 1 1 50.0% 
 
Cerebrovascular accident 0 1 0.0% 
 
Cerebral infarction 1 0 50.0% 
 
Hemorrhagic stroke 1 0 100.0% 
  Ischemic stroke 1 1 33.3% 
No SDR Acute myocardial infarction 0 20   
 
Atrioventricular block complete 1 18   
 
Cardiogenic shock 0 18   
 
Myocardial infarction 1 14   
 
Arteriosclerosis coronary artery 1 19   
 
Cardiac arrest 0 19   
 
Cardiac failure 0 18   
 
Cardiac failure congestive 4 15   
 
Sudden death 0 18   
 
Sudden cardiac death 0 19   
 
Cerebrovascular accident 3 17   
 
Cerebral infarction 1 19   
 
Hemorrhagic stroke 0 20   
  Ischemic stroke 1 18   







eTable 1: Drugs used in Cardiovascular Subset 
 
FDA Approved DPP-4 Inhibitors  
alogliptin 
alogliptin and metformin 
alogliptin and pioglitazone 
linagliptin 
linagliptin and empagliflozin 
linagliptin and metformin 
sitagliptin 
sitagliptin and metformin 
sitagliptin and metformin extended release 
saxagliptin 
saxagliptin and metformin extended release 
FDA Approved Sulfonylureas  
chlorpropamide 
glimepiride 
glimepiride and pioglitazone hydrochloride 
glimepiride and rosiglitazone maleate 
glipizide 
glipizide extended release 
glyburide 
glyburide and metformin hydrochloride 
FDA Approved Biguanides*  
metformin hydrochloride 
metformin hydrochloride extended release 





FDA Approved Thiazolidinediones  
alogliptin benzoate and pioglitazone hydrochloride 
metformin hydrochloride and rosiglitazone maleate 
metformin hydrochloride and pioglitazone hydrochloride 
metformin hydrochloride and pioglitazone hydrochloride extended release 
pioglitazone hydrochloride 
rosiglitazone maleate 
FDA Approved SGLT2 Inhibitors*  
canagliflozin 
canagliflozin and metformin 
dapagliflozin 
dapagliflozin and metformin extended-release 
empagliflozin 
empagliflozin and linagliptin 
empagliflozin and metformin 
FDA Approved Meglitinides*  
nateglinide 
repaglinide 
repaglinide and metformin hydrochloride 















atorvastatin calcium; ezetimibe 
extended release niacin; lovastatin 
FDA Approved Fibrates  
fenofibrate 
choline fenofibrate 
FDA Approved Niacin/Nicotinic Acid  
niacin extended release 




















propranolol hydrochloride extended release 
propranolol hydrochloride sustained release 
sotalol hydrochloride 
timolol maleate 
bendroflumethiazide; nadolol  
hydrochlorothiazide; propranolol hydrochloride  
hydrochlorothiazide; metoprolol succinate  
metoprolol succinate extended release 
pindolol 












amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil 






nebivolol hydrochloride; valsartan 
FDA Approved Angiotensin Converting Enzyme Inhibitors  
lisinopril 
enalapril maleate/diltiazam malate 
trandolapril 
captopril; hydrochlorothiazide 
FDA Approved Calcium Channel Blockers  
diltiazem hydrochloride 
verapamil extended release 
verapamil 
verapamil hydrochloride sustained release 
enalapril maleate; felodipine 
isradipine extended release 
amlodipine besylate; olmesartan medoxomil 
amlodipine besylate; atorvastatin calcium 
clevidipine 
aliskiren hemifumarate; amlodipine besylate 
aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide 
nimodipine 
amlodipine besylate; perindopril arginine 










FDA Approved Diuretics  
atenolol; chlorthalidone 




FDA Approved Anticoagulants  
 apixaban 
 ardeparin sodium 
 argatroban 
 bivalirudin 
 dabigatran etexilate mesylate 
 edoxaban tosylate 
 rivaroxaban 
 ticagrelor 
 tinzaparin sodium 
 warfarin sodium 
FDA Approved Nitrates  
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 hydralazine hydrochloride; isosorbide dinitrate 
 isosorbide 
 isosorbide dinitrate 
 isosorbide mononitrate 
 nitroglycerin 
 riociguat 
FDA Approved Antihypertensive  
 treprostinil 
FDA Approved Antianginals  
 ranolazine 
FDA Approved Endothelin Receptor Antagonist  
 ambrisentan 
 macitentan 
FDA Approved Dyslipidemic Agents  
 icosapent ethyl 
 omega-3 carboxylic acids 
FDA Approved Direct Renin Inhibitor  
 aliskiren hemifumarate 
FDA Approved MTP Inhibitors  
 lomitapide mesylate 









FDA Approved Vasodilators  
 hydralazine hydrochloride 
 hydralazine hydrochloride; hydrochlorothiazide 
 hydralazine hydrochloride; hydrochlorothiazide; reserpine 




FDA-Approved Alpha Adrenoreceptor Agonists  
 chlorthalidone; clonidine hydrochloride 
 chlorthiazide; methyldopa 
 clonidine 
 clonidine hydrochloride 
 guanabenz acetate 
 hydrochlorothiazide; methyldopa 
 methyldopa 




eTable 2: Summary of safety signals for DPP-4 Inhibitors† 
      
Bayesian 
Disproportionality 






Adverse Event Drug EB05‡ EBGM‡ EB05‡ EBGM‡ 
Cardiac Disorders 
  acute myocardial infarction alogliptin 1.34 1.94 0.68 0.93 
    sitagliptin 1.65 2.00 0.81 0.97 
    
sitagliptin and 
metformin 0.45 3.54 0.14 0.81 
 
cardiogenic shock sitagliptin 0.93 1.34 0.52 0.74 
  myocardial infarction alogliptin 15.89 19.78 4.48 5.57 
    saxagliptin     9.98 12.12 
    sitagliptin 0.95 1.11 0.46 0.53 
    
sitagliptin and 







sitagliptin 0.90 1.25 0.39 0.53 
  cardiac arrest linagliptin 0.29 10.73 0.28 17.20 
    saxagliptin     7.17 7.56 
    sitagliptin 0.46 0.70 0.71 1.13 
    
sitagliptin and 
metformin 0.16 0.44 0.13 0.70 
 











sitagliptin 0.16 0.21 1.01 1.34 
  cardiac failure congestive saxagliptin     0.97 1.24 
    sitagliptin 0.51 0.61 0.28 0.33 
    
sitagliptin and 
metformin 0.43 0.65 0.23 0.35 
Generic Disorders and Administration Site Conditions 
  sudden death alogliptin 1.97 5.73 3.57 7.82 
    saxagliptin     30.99 32.93 
    sitagliptin 0.10 0.19 0.06 0.15 
    
sitagliptin and 
metformin 0.15 0.40 0.06 0.32 
 
sudden cardiac death saxagliptin 
  
98.70 103.74 
†Excludes products with n=0 reports, EB05 <0, or EBGM <0 
‡ EBGM = empirical Bayes geometric mean of the relative reporting ratio; EB05=90% lower bound of EBGM 
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eTable 2 (cont'd): Summary of safety signals for DPP-4 Inhibitors† 
      
Bayesian 
Disproportionality 







Adverse Event Drug EB05‡ EBGM‡ 
EB05
‡ EBGM‡ 
Nervous System Disorders 
     
  
cerebrovascular 
accident alogliptin     606.37 1069.46 
    linagliptin 0.33 73.47 0.31 21.83 
    saxagliptin     3.15 4.33 
    sitagliptin 1.45 1.71 0.74 0.87 
    sitagliptin and metformin 0.06 0.14 0.01 0.07 
    
sitagliptin and metformin 
extended release 0.34 771.41 0.80 229.17 
 






sitagliptin 2.47 2.93 2.81 3.27 
  hemorrhagic stroke sitagliptin 0.25 0.47 0.12 0.26 
 




sitagliptin 0.13 0.28 0.04 0.13 
†Excludes products with n=0 reports, EB05 <0, or EBGM <0 






eTable 3: Summary of safety signals for Sulfonylureas† 
      
Bayesian 
Disproportionality 











infarction glimepiride 1.98 2.22     
    glipizide 139.18 167.58 33.46 38.15 
    glipizide extended release 0.45 0.86 0.21 0.41 
    glyburide 1.13 1.36 0.55 0.66 
    
glyburide and metformin 
hydrochloride 0.91 1.45 0.46 0.70 
 
atrioventricular 
block complete glimepiride 9.92 10.86 
  
  
glipizide 0.79 1.11 
  
  
glyburide 7.66 8.75 2.50 2.86 
  
glyburide and metformin 
hydrochloride 0.19 0.56 0.48 3.33 
 cardiogenic shock glimepiride 1.23 1.74     
    glipizide 1.71 2.11 3.34 4.28 
    glyburide 1.04 1.39 0.58 0.76 
    
glyburide and metformin 
hydrochloride 4.57 6.46 2.58 3.55 
 
myocardial 
infarction chlorpropamide 27.94 34.82 13.41 16.70 
  
glimepiride 1.69 1.82 
  
  
glipizide 2.75 2.94 2.01 2.27 
  
glipizide extended release 36.59 38.75 17.55 18.58 
  
glyburide 1.34 1.49 0.65 0.72 
  
glyburide and metformin 
hydrochloride 2.09 2.59 1.03 1.24 
  
arteriosclerosis 
coronary artery glimepiride 4.13 4.94     
    glipizide 0.98 1.24 0.07 0.19 
    glyburide 0.90 1.19 0.39 0.51 
 
cardiac arrest glimepiride 0.75 0.82 
  
  
glipizide 0.73 0.81 0.45 0.59 
  
glipizide extended release 0.26 0.41 0.21 0.35 
  
glyburide 1.95 2.11 1.67 1.80 
  
glyburide and metformin 
hydrochloride 44.11 52.51 38.48 44.83 
 † Excludes products with n=0 reports, EB05 <0, or EBGM <0 
   ‡ EB05: 90% lower bound of the empirical Bayes geometric mean of the relative reporting ratio   




eTable 3 (cont'd): Summary of safety signals for Sulfonylureas† 
      
Bayesian 
Disproportionality 







Adverse Event Drug EB05‡ EBGM§ EB05‡ 
EBGM
§ 
  cardiac failure glimepiride 0.62 0.69     
    glipizide 0.28 0.34 0.22 0.34 
    glyburide 0.27 0.34 0.90 1.45 
    
glyburide and metformin 
hydrochloride 0.43 0.63 0.31 0.47 
 
cardiac failure 
congestive glimepiride 2.44 2.69 1.34 1.46 
  
glimepiride and pioglitazone 
hydrochloride 2.42 18.34 1.64 5.96 
  
glimepiride and 
rosiglitazone maleate 7.28 16.34 2.38 5.31 
  
glipizide 4.79 5.01 23.67 27.09 
  
glipizide extended release 1.65 2.15 0.92 1.17 
  
glyburide 3.29 3.52 1.79 1.91 
  
glyburide and metformin 
hydrochloride 2.66 3.19 1.48 1.73 
Generic Disorders and Administration Site Conditions 
  sudden death glimepiride 0.32 0.44     
    glipizide 0.39 0.54     
    glyburide 0.54 0.75 0.42 0.60 
 
sudden cardiac death glipizide 0.35 0.51 
  Nervous System Disorders 
  
cerebrovascular 
accident glimepiride 2.11 2.45 1.09 1.24 
    
glimepiride and pioglitazone 
hydrochloride 0.49 1.47 0.25 0.75 
    
glimepiride and 
rosiglitazone maleate 3.16 4.91 1.77 2.50 
    glipizide 0.77 0.89 0.46 0.64 
    glipizide extended release 0.52 0.88 0.26 0.45 
    glyburide 1.82 2.06 0.93 1.05 
    
glyburide and metformin 
hydrochloride 1.38 1.93 0.73 0.98 
 
cerebral infarction glimepiride 3.97 4.32 
  
  
glipizide 0.14 0.20 
  
  
glyburide 1.72 2.03 1.94 2.26 
  
glyburide and metformin 
hydrochloride 0.12 0.25 0.08 0.28 
 hemorrhagic stroke glimepiride 0.42 0.76     
    glipizide 0.67 0.97     
 
ischemic stroke glimepiride 9.54 11.27 
  
  
glipizide 0.49 0.76 
  
  
glyburide 0.75 1.19 0.35 0.54 
† Excludes products with n=0 reports, EB05 <0, or EBGM <0 
  ‡ EB05: 90% lower bound of the empirical Bayes geometric mean of the relative reporting ratio   




eTable 4: Summary of safety signals for Biguanides† 
      
Bayesian 
Disproportionalit







Adverse Event Drug EB05‡ EBGM§ EB05‡ EBGM§ 
Cardiac Disorders 
     
  
acute myocardial 
infarction metformin hydrochloride 0.58 0.71 0.28 0.34 
 
atrioventricular block 
complete metformin hydrochloride 12.70 13.85 4.15 4.52 
 cardiogenic shock metformin hydrochloride 4.06 4.59 2.25 2.52 
 








coronary artery metformin hydrochloride 0.59 0.77 0.25 0.33 
 
cardiac arrest metformin hydrochloride 0.24 0.28 0.24 0.28 
 cardiac failure metformin hydrochloride 16.12 17.31 6.45 6.94 
 
cardiac failure 






Generic Disorders and Administration Site Conditions         
  sudden death metformin hydrochloride 1.54 2.46 2.26 3.35 
 
sudden cardiac death metformin hydrochloride 62.94 67.32 18.14 19.34 
Nervous System Disorders           
  
cerebrovascular 
accident metformin hydrochloride 2.68 2.92 1.37 1.49 
  
metformin hydrochloride 
extended release 0.77 6.24 0.75 3.17 
 
cerebral infarction metformin hydrochloride 0.60 0.73 0.67 0.81 
 hemorrhagic stroke metformin hydrochloride 5.04 5.84 2.81 3.24 
 
ischemic stroke metformin hydrochloride 87.66 101.97 27.52 31.15 
† Excludes products with n=0 reports, EB05 <0, or EBGM <0 
  ‡ EB05: 90% lower bound of the empirical Bayes geometric mean of the relative reporting ratio   
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Purpose: Cardiovascular safety of Dipeptidyl peptidase-IV inhibitors (DPP-4i) is poorly 
understood for patients with type 2 diabetes.  Understanding this risk is especially 
important given that type 2 diabetes independently increases an individual’s risk for 
cardiovascular disease.  Clinical trials investigating this association focused on patients 
with high cardiovascular risk; however, this approach excludes the majority of new users 
of antihyperglycemic therapy who do not have a history of cardiovascular or renal 
disease.  As such, we investigated the risk of major adverse cardiovascular events 
(MACE) associated with the use of DPP-4i among patients with diabetes, without 
established cardiovascular disease or renal disease.  Because DPP-4i are recognized for 
their low cardiovascular risk, we restricted to this “low-risk” patient population to control 
for potential confounding due to existing cardiovascular disease or renal disease.  
 
Methods: Using a new-user, cohort design, we analyzed Truven Marketscan Commercial 
Claims and Encounters from 2010-2015 for commercially insured patients with diabetes, 
without a history of cardiovascular disease and/or chronic kidney disease to determine the 
association between DPP-4i and MACE.  We compared time to first MACE for DPP-4i 
to sulfonylurea and DPP-4i to metformin using propensity score weighted Cox 
proportional hazards, adjusting for demographics, baseline comorbidities, concomitant 
medications, and cumulative exposure. Additionally, we assessed the association between 
DPP-4i and the secondary outcomes of heart failure, acute myocardial infarction, and 




Results: Of 445,701 individuals, 30,267 (6.79%) used DPP-4i, 52,138 (11.70%) used 
sulfonylureas, and 367,908 (82.55%) used metformin.  Incidence for MACE with DPP-4i 
(21.45 per 1,000 person-years) was lower than sulfonylurea (24.87 per 1,000 person-
years) and comparable to metformin (17.61 per 1,000 person-years).  After adjustment, 
DPP-4i use was associated with lower risk than sulfonylurea use (aHR=0.87; 95% CI: 
[0.78, 0.98]), and similar risk to metformin use (aHR=1.07; 95% CI: [0.97, 1.18]).  Risk 
for acute myocardial infarction (aHR=0.70; 95% CI: [0.51, 0.96]), stroke (aHR=0.57; 
95%CI: [0.41, 0.79]), and heart failure (aHR=0.57; 95% CI: 0.41, 0.79) with DPP-4i was 
statistically significantly lower compared to sulfonylureas. 
 
Conclusions: Among low-risk individuals, DPP-4i use was associated with lower risk for 
MACE compared to sulfonylureas and no increased risk for MACE compared to 
metformin.  These findings suggest that DPP-4i is a low cardiovascular risk option for 
low-risk patients initiating antihyperglycemic treatment.   
 
Keywords 
Dipeptidyl peptidase-IV inhibitors; drug-related side effects and adverse reactions; major 





Type 2 diabetes is prevalent in 9.4% of the United States population, affecting 
individuals of different races, ages, and socio-economic backgrounds1.  The long-term 
micro- and macro-vascular complications of diabetes compound the public health impact 
of the disease2.  Additionally, diabetes often presents in patients with multiple 
comorbidities, many of which affect the cardiovascular system3.  Of the 7.2 million 
hospital discharges for patients with diabetes in 2014, 1.5 million were for cardiovascular 
events1.  Altering the risk for major adverse cardiovascular events (MACE) involves a 
nuanced understanding of a patient’s blood glucose levels, comorbidities, and vascular 
complications.   
 
Further complicating this risk management, clinical trials and retrospective cohort 
studies have linked some oral antihyperglycemic drug classes, such as thiazolidinediones4 
and sulfonylureas5 to an increased risk of MACE.  Determining whether these 
associations are due to underlying cardiovascular disease or to adverse reactions from a 
particular drug remains a challenge for regulators and practitioners6.  One newer class of 
oral antihyperglycemic agents, dipeptidyl peptidase-IV inhibitors (DPP-4i), has elicited 
increased reports of MACE to the United States Food and Drug Administration Adverse 
Event Reporting System7,8.  These drugs were initially believed to be cardio-protective in 
pre-market clinical pharmacology studies9.  However, postmarketing clinical trials10-12 
and retrospective, insurance claims-based cohort studies13-15 have reported inconsistent 
data regarding the cardiovascular safety of DPP-4i.  Additionally, the clinical trials have 
focused primarily on individuals with established cardiovascular disease, while the 
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insurance claims-based cohort studies have focused on all diabetic patients exposed to 
DPP-4i, irrespective of established cardiovascular or renal disease.  Given that the 
majority of new users of oral antihyperglycemic agents do not have established 
cardiovascular or renal disease, we sought to better understand cardiovascular safety of 
DPP-4i for this population in a real-world setting.   
 
Using a nationwide commercial claims database, we investigated the association 
between DPP-4i therapy and MACE.  We restricted the study population to those without 
diagnosed cardiovascular disease or renal disease and compared the risk of MACE 
among new users of DPP-4i to that of metformin and of sulfonylurea.  By restricting the 
population to those without a baseline risk, we were able to assess whether DPP-4i was 
associated with increased risk for MACE among a large subtype of patients initiating 
antihyperglycemic treatment.  Underlying cardiovascular disease and renal disease 
confound the relationship between DPP-4i therapy and MACE.  As such, prescribers 
have different prescribing considerations depending on an individual’s cardiovascular 
risk.  We were interested in this low risk population, as any difference in risk for MACE 
with DPP-4i would inform the prescribing of DPP-4i.  Current package labels in the US 
only include warnings about the need for caution when prescribing these drugs to patients 









Study Design and Data Source 
To investigate the association between DPP-4i and MACE, we conducted a 
retrospective cohort study of commercially insured patients, using data from Truven 
Marketscan Commercial Claims and Encounters from January 2010 through December 
2015.  This database captures individual-level linked patient claims and encounter data 
for approximately 25 million individuals annually.  The de-identified data contains 
information on patient demographics, inpatient and outpatient services as well as 
prescription drug claims.   
 
Study Population 
We identified patients with type 2 diabetes as those with at least one prescription 
for an oral antihyperglycemic agent and either HbA1c greater than 6.5% twice, fasting 
glucose greater than 126 mg/dL twice on different days, random glucose > 200 mg/dL 
twice on different days, one inpatient diagnosis (International Classification of Diseases, 
9th/10th Revisions (ICD-9(10)): 250x (E11.9), 357.2 (E11.42), 366.41 (E11.36), 362.01-
362.07 (E11.3*)), or outpatient diagnosis (ICD-9(10): 250x (E11.9), 366.41 (E11.36), 
362.01-362.07 (E11.3*)) twice on different days.  We included patients if they received 
at least one prescription for an FDA-approved DPP-4i, sulfonylurea, or metformin 
(eTable 1).  The index date for follow-up was assigned as the date of first filled 
prescription for one of these products.  The baseline period was defined as the six-month 
period preceding this. 
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We excluded individuals if they met any of the following criteria: 1) less than six 
months of continuous medical and prescription enrollment, 2) less than 12-weeks of 
continuous exposure to exposure group drugs, 3) insulin use during baseline period, 4) 
treatment with other oral or injectable antihyperglycemic agents in baseline period, 5) 
below the age of 35, 6) cardiovascular disease or renal disease in baseline, and 7) missing 
age or sex information.  We followed patients until the first of the following events: 1) 
first evidence of a major adverse cardiovascular event (MACE), 2) end of continuous 
medical or prescription enrollment, 3) switch in antihyperglycemic agent treatment or 
addition of another antihyperglycemic agent, 4) 14-days after then last date of exposure 
to exposure group drug, or 5) study end date of December 31, 2015.   
 
We identified individuals with established cardiovascular disease through ICD-
9/10 codes for myocardial infarction, complete atrioventricular block, cardiogenic shock, 
coronary artery disease, chronic heart failure, stroke, cerebral infarction, atrial 
fibrillation, or coronary artery bypass graft in the six-month baseline period.  We also 
defined renal disease through ICD-9/10 codes for chronic kidney disease or acute renal 
failure in the six-month baseline period. 
 
Definition of Exposure 
The three exposure groups consisted of new users of DPP-4i, sulfonylurea, and 
metformin, respectively.  We also created an indicator variable for cumulative exposure, 
defined as the number of days an individual was exposed to the exposure group drug.  In 
the event of an individual initiating more than one of these drug classes at baseline, they 
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were assigned to all relevant exposure groups.  We used a negative control (metformin) 
and a positive control (sulfonylurea) in this study for two reasons: 1) the population of 
new users of DPP-4i is similar to that of sulfonylurea; however, sulfonylurea is carries 
cardiovascular risk; 2) metformin carries low cardiovascular risk; however, new users of 
metformin have less severe diabetes. 
 
Definition of Outcomes 
We defined our primary composite outcome of MACE as the first of any of the 
following events: myocardial infarction, cardiac arrest, coronary artery bypass graft, 
coronary angioplasty, heart failure, and stroke.  Myocardial infarction16,17, cardiac 
arrest18, coronary artery bypass graft16, coronary angioplasty16, heart failure19, and 
stroke20 were identified through validated ICD-9/10 algorithms.  For 
conditions/procedures without validated ICD-10 algorithms, we deferred to the Chronic 
Conditions Warehouse21.  We excluded all-cause mortality from the primary composite 
outcome, because we did not have information on deaths occurring outside of the 
inpatient setting.  Our secondary outcomes were acute myocardial infarction, stroke, and 
heart failure.   
 
Definition of Covariates 
We assessed possible confounding due to individual demographics, concomitant 
medications, and comorbidities.  We conducted literature searches of similar studies17,22-
24, consulted clinical guidance25-28, and regulatory documents29 to identify covariates of 
interest.  We created indicator variables for individuals’ age and sex.  We accounted for 
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comorbidities such as hypertension, asthma, peripheral vascular disease, and neuropathy 
using the Clinical Classification Software (CCS) developed by the Agency for Healthcare 
Research and Quality.  The CCS was only available for conditions coded in ICD-9.  For 
inpatient and outpatient medical service records using ICD-10, we cross-referenced ICD-
9 codes with their ICD-10 equivalents.  Additionally, we identified the use of 
concomitant medication such as statins, hormone replacement therapy, bronchodilators, 
and diuretics via National Drug Codes (NDC).  Finally we categorized individuals based 
on their disease severity using the Adjusted Diabetes Comorbidities Severity Index 
(aDCSI)30-32.  A full list of covariates used in the analysis is contained in eTable 2. 
 
Propensity Score  
We first identified all available covariates without an association to the exposure 
that were associated to the primary outcome in order to increase precision33.  Next, we 
used the Toolkit for Weighting and Analysis of Nonequivalent Groups (twang) package 
developed by the RAND Corporation34 to compute the propensity scores and associated 
weights used in the analysis to balance the covariates between exposure groups.  This 
package allows for propensity scores estimation in the presence of multiple exposure 
groups.  Using generalized boosted regression models, we optimized the selection of 
covariates for the propensity score calculation.  We used the standardized mean 
difference (SMD) to measure the balance of covariates before and after weighting.  
Propensity score weighting reduced the SMD from a maximum of 0.15 to less than 0.01 
(eFigure 1).  We then used the average treatment effect on the treated (ATT) propensity 




We used chi-square statistics for categorical covariates and the Kruskal-Wallis 
test for continuous covariates to compare differences at baseline between new users of 
DPP-4i, sulfonylurea, and metformin.  Next, we used exact Poisson tests to compute the 
incidence rate differences for the primary and secondary outcomes between new users of 
DPP-4i and those of sulfonylurea and metformin, respectively.  Additionally, we checked 
for differences in time to first MACE distributions using a Kolmogorov-Smirnov test.  
We calculated propensity score weighted crude and adjusted Cox proportional hazards 
for the association between new use of DPP-4i and the primary and secondary outcomes 
compared to new use of sulfonylureas and metformin.  We included indicators for age, 
sex, baseline comorbidities, and concomitant medication in the adjusted models (eTable 
3).  We plotted the scaled Schoenfeld residuals to check for covariates that violated the 
proportional hazards assumption.  We stratified the Cox proportional hazards model by 
covariates that violated the proportional hazards assumption.  Finally, we included 
natural regression spline terms with knots at 180-, 365-, and 540-days to account for 
changes in the underlying hazard function with increasing cumulative exposure, which 
was defined as the total number of days exposed to the exposure group drug35.  All 
analyses were conducted in R, version 3.3.3. 
 
Sensitivity Analyses 
To check the robustness of our results, we first assessed possible sensitivity of our 
results to the latency of the period after drug discontinuation.  We lagged this period for 
14-, 7-, and 30-days after the last day of exposure to drug.  Next, we recalculated the 
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primary analysis without individuals exposed to more than one exposure group to 
determine whether our results were sensitive to the inclusion of those individuals.   
 





Subject Inclusion and Characteristics 
We first identified 12,166,812 individuals with diabetes from January 2010-
December 2015 through commercial claims.  Most individuals in each exposure group 
were male (DPP-4i: 58.86%, sulfonylureas: 58.19%, metformin: 51.34%) (Figure 1).  
More individuals on DPP-4i (41.51%) and sulfonylureas (44.52%) were aged 55 and 
older compared to those on metformin (36.37%).  After applying the inclusion and 
exclusion criteria above, the study population consisted of 445,701 individuals.  There 
were 30,267 (6.79%) new users of DPP-4i, 52,138 (11.70%) who initiated sulfonylureas, 
and 367,908 (82.55%) who started metformin.  Less than one percent of included 
individuals were new users of both DPP-4i and metformin, and 17,070 (3.83%) were new 
users of both sulfonylureas and metformin.   
 
Individuals in each exposure group differed in their baseline characteristics 
(Table 1).  There were more male new users of sulfonylureas (58.19%) than DPP-4i 
(56.86%) or metformin (51.34%).  Most individuals in each group were exposed for 12 
months or less (DPP-4i: 77.94%; sulfonylurea: 76.27%; metformin: 72.41%).  Many 
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individuals in this study cohort experienced micro-vascular complications of diabetes.  
New users of DPP-4i had neuropathy (7.53%), retinopathy (5.48%), and peripheral 
vascular disease (2.79%) in the baseline period.  Among new users of sulfonylurea, 
6.93% had neuropathy, 5.04% had retinopathy, and 2.17% had peripheral vascular 
disease.  Metformin users had the lowest proportion of peripheral vascular disease 
(1.87%), retinopathy (3.50%), and nephropathy (0.54%).  Additionally, a higher 
percentage of DPP-4i initiators (22.3%) used angiotensin II receptor blockers in baseline 
compared to sulfonylurea (16.2%) and metformin (16.5%) initiators.  Statin use was also 
higher in DPP-4i initiators (42.5%) than sulfonylurea (37.5%) and metformin (37.9%).  
Differences in baseline characteristics between exposure groups were diminished after 
propensity score weighting (eTable 6). 
 
Association Between Treatment and Major Adverse Cardiovascular Events 
The median follow-up for first occurrence of MACE was 341 days [interquartile 
range (IQR): 196, 580], and there were no significant differences in follow-up time 
between exposure groups (eFigure 2).  The absolute difference in incidence rates for the 
primary composite outcome was statistically significantly greater for DPP-4i (21.45 per 
1,000 person-years) compared to metformin (17.61 per 1,000 person years). DPP-4i was 
also associated with a lower incidence rate of MACE than sulfonylurea (24.87 per 1,000 
person-years) (Table 2). This difference was also seen in the secondary outcomes of 
acute myocardial infarction (DPP-4i: 2.45 per 1,000 person-years vs. sulfonylurea: 3.72 
per 1,000 person-years), stroke (DPP-4i: 2.21 per 1,000 person-years vs. sulfonylurea: 
4.08 per 1,000 person-years), and heart failure (DPP-4i: 2.21 per 1,000 person-years vs. 
 
 65 
sulfonylurea: 4.02 per 1,000 person-years).  There were no differences in incidence 
between DPP-4i and metformin for the secondary outcomes.   
 
After adjustment for baseline characteristics, introducing spline terms for every 
six months of cumulative exposure, and propensity score weighting, there was an 
association between DPP-4i and MACE compared to sulfonylurea and MACE (adjusted 
hazard ratio (aHR): 0.87, 95% confidence interval (CI): 0.78, 0.98).  In contrast, there 
was no difference in risk for MACE with DPP-4i compared to metformin (aHR: 1.07, 
95% CI: 0.97, 1.18) (Table 3).   
 
There were also differences in risk  seen for the secondary outcomes between 
exposure groups.  In the adjusted analyses, there was a lower risk for acute myocardial 
infarction associated with DPP-4i (aHR: 0.70, 95% CI: 0.51, 0.96) compared to 
sulfonylurea (aHR: 0.95, 95% CI: 0.72, 1.27).  Risk for stroke was also lower with DPP-
4i (aHR: 0.57, 95% CI: 0.41, 0.79) compared to sulfonylurea (aHR: 0.81, 95% CI: 0.60, 
1.09).  Finally DPP-4i (aHR: 0.57, 95% CI: 0.41, 0.79) was associated with a lower risk 
for heart failure compared to sulfonylurea (aHR: 1.04, 95% CI: 0.77, 1.40).  There were 
no statistically significant associations between the secondary outcomes and DPP-4i 
when compared to metformin in the adjusted or unadjusted analyses (Table 3).   
 
Sensitivity Analyses 
After removing individuals with more than one exposure group, there were a total 
of 426,328 individuals in the study cohort.  Analysis results did not qualitatively differ 
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after removal of these individuals (eTable 3).  Additionally, results were not sensitive to 
changes in the latency period after the last dose of exposure for the primary analysis 




In this retrospective cohort analysis of commercial claims data for individuals 
with diabetes and without a history of cardiovascular disease or chronic kidney disease, 
DPP-4i use was associated with 13% lower risk of MACE compared to sulfonylureas, 
and a similar risk of MACE when compared to metformin.  DPP-4i was also shown to be 
associated with a decreased risk for acute myocardial infarction, stroke, and heart failure 
when compared to sulfonylurea.  These results contribute to the existing data from signal 
detection of adverse event reports, clinical trials, and other cohort analyses examining the 
association of DPP-4i and MACE in low cardiovascular risk patients with diabetes. 
 
The results of this study align with those of previous clinical trials and 
observational studies of cardiovascular safety of DPP-4i.  Unlike the three completed 
clinical trials comparing DPP-4i and placebo11,36,37; however, our study population 
consisted of individuals with low-risk for MACE but in a real-world setting with multiple 
comorbidities and concomitant medications.  Our results confirm that DPP-4i are similar 
to metformin and potentially safer than sulfonylureas with regards to risk of MACE in a 
low-risk subset of new users.  Additionally, our analysis compared DPP-4i to other 
common first-line therapies, as opposed to assessing it as add-on therapy compared to 
placebo, and showed a decreased risk for MACE compared to sulfonylureas.  Of note, we 
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did not find increased risk for heart failure with the use of DPP-4i, contrasting with the 
results of the EXamination of CArdiovascular OutcoMes with AlogliptIN versus 
Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary 
Syndrome (EXAMINE) trial10 and the Saxagliptin Assessment of Vascular Outcomes 
Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI) trial11.  This could be due to 
our restricting the study cohort to low-risk individuals.   
 
Similar to our study, a 2015 longitudinal study of the Taiwan National Health 
Insurance Research Database showed lower risk for MACE associated with DPP-4i 
compared to sulfonylurea as add-on therapy to metformin (aHR: 0.68, 95% CI: 0.55, 
0.83)13.  Our study population expanded on this approach through the inclusion of 
individuals exposed to only metformin.   
 
This analysis had two notable strengths.  The first of these was the use of a low-
risk population together with a new user design.  This approach allowed us to hone in on 
a common prescribing scenario, as many patients initiating oral antihyperglycemic 
therapy are middle-aged and do not have cardiovascular disease or renal disease.  
Understanding whether or not diabetic treatment in this population increases patient risk 
for MACE is critical to managing their care due to the close link between cardiovascular 
disease and diabetes38.  
 
There were also limitations with our analysis.  The first of these was the inclusion 
of individuals into more than one exposure group at baseline.  We recognize that this 
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could have potentially led to misclassification39.  Excluding patients who were exposed to 
multiple drug groups of interest would have resulted in a 32.7% reduction in our 
population of individuals exposed to sulfonylurea, potentially threatening the 
generalizability of our results.  As such, we assessed the sensitivity of our results to their 
inclusion and found them to be robust.  The second limitation was our inability to account 
for time-varying hazards.  We attempted to address this by introducing natural regression 
spline terms with knots at 6-, 12-, and 18-months of cumulative exposure.  This allowed 
us to account for possible changes in baseline hazard with increasing cumulative 
exposure.  Third, there is the potential for informative censoring due to a change in 
exposure status.  We assessed sensitivity of our results to this approach to censoring and 
found them to be insensitive to the lagged latency period after the last day of exposure.  
Additionally, MACE primarily occurred within the first year of exposure and extending 
the latency period past 30-days would have unlikely changed our results and could have 
potentially led to misclassification. Finally due to limitations of the dataset, we were 
unable to assess key unmeasured variables.  The first of these was mortality, which we 
could not include as a component of the primary composite outcome or as a competing 
risk.  We also did not have data on body mass index, a correlate of cardiovascular 
disease.  Third, our study population consisted of younger, low-risk patients with diabetes 
below age 65.  As we were interested in those with low-cardiovascular risk, this younger 








Among a commercially insured patient population with diabetes and low-risk for 
major adverse cardiovascular events in the United States, our results provide evidence of 
decreased risk for MACE when comparing DPP-4i versus sulfonylurea.  Additionally, we 
found that DPP-4i carried similar risk for MACE when compared to metformin.  These 
results were also reflected in several individual components of the composite outcome, 
namely acute myocardial infarction, stroke, and heart failure.  Finally, our results suggest 
that DPP-4i is a low cardiovascular risk option for low-risk patients initiating 
antihyperglycemic treatment.  Additionally our findings of no association with increased 
risk for heart failure in a low-risk population suggests that the current drug label warning 
for caution in prescribing saxagliptin and alogliptin in patients with prior cardiovascular 
disease is sufficient.  Further research is needed to investigate whether this association 
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TABLES AND FIGURES 
 
Figure 1. Cohort derivation and sample attrition 
 
1 OHA = oral antihyperglycemic agents 
2 Subcategories are not mutually exclusive 
Diabetic Patients in Truven Marketscan 2010-15 
(N=12,166,812) 
Total patients exposed to DPP-4i, Sulfonylurea, or Metformin 
(N=2,741,571) 
Total excluded for pre-defined criteria 
(N=1,969,032)2  
   - <6mo enrollment in baseline:    
      1,216,312 
   - Insulin users: 545,836 
   - Under age 35: 206,884 
   - CVD or renal impairment in  
      baseline: 113,296) 




   - DPP-4i (n=9,146) 
   - Sulfonylurea (n=17,481) 
   - Metformin (n=88,596) 
 












  N % N % N % 
Demographics           
 Male 17,209 56.86 30,340 58.19 188,882 51.34 
Age   
 
      
 35-44 5,562 18.38 9,578 18.37 82,260 22.36 
45-54 12,140 40.11 19,348 37.11 151,847 41.27 
55-64 12,565 41.51 23,212 44.52 133,801 36.37 
Location (Region)           
 Northeast  5,829 19.26 7,358 14.11 56,186 15.27 
North Central 5,614 18.55 10,635 20.40 79,433 21.59 
South 14,926 49.31 25,108 48.16 160,626 43.66 
West 3,391 11.20 8,203 15.73 65,961 17.93 
Unknown 507 1.68 834 1.60 5,702 1.55 
            
 Cumulative Exposure           
 <6 months 13,110 43.31 24,428 46.85 141,469 38.45 
6-12 months 10,481 34.63 15,339 29.42 124,943 33.96 
12-18 months 3,456 11.42 5,971 11.45 49,787 13.53 
>18 months 3,220 10.64 6,400 12.28 51,709 14.05 
            
 Comorbidities in Baseline           
 Asthma 1,823 6.02 2,578 4.94 25,700 6.99 
Peripheral Vascular 
Disease 845 2.79 1,134 2.17 6,886 1.87 
Ischemic heart disease 1,201 3.97 1,861 3.57 11,364 3.09 
Hypertension 18,907 62.47 30,789 59.05 215,790 58.65 
Retinopathy 1,659 5.48 2,630 5.04 12,870 3.50 
Eye disease 8,009 26.46 11,759 22.55 86,274 23.45 
Renal disease 7,390 24.42 11,008 21.11 84,100 22.86 
Atrial fibrilation 2,070 6.84 2,988 5.73 26,749 7.27 
Neuropathy 2,280 7.53 3,612 6.93 27,841 7.57 
Nephropathy 279 0.92 589 1.13 2,000 0.54 
aDCSI Score           
      0 30,115 99.50 51,845 99.44 366,471 99.61 
     1+ 152 0.50 293 0.56 1,437 0.39 
       
Dual Exposures           
 Sulfonylureas   0.00   0.00 17,070 4.64 
Metformin 2,303 7.61 17,070 32.74   0.00 












  N % N % N % 
Concomitant Medications at 
Baseline           
 ACE inhibitors 5,856 19.35 11,255 21.59 84,735 23.03 
angiotensin II receptor  
blockers 6,746 22.29 8,467 16.24 60,645 16.48 
antidepressants 4,648 15.36 6,933 13.30 71,046 19.31 
antiplatelets 3,609 11.92 5,353 10.27 46,484 12.63 
Asthma medication 819 2.71 1,225 2.35 10,656 2.90 
α-Glucosidase inhibitors 58 0.19 80 0.15 184 0.05 
benzodiazepines 3,195 10.56 4,844 9.29 46,310 12.59 
beta blockers 4,165 13.76 7,640 14.65 57,142 15.53 
bile acid sequestrants 526 1.74 644 1.24 4,081 1.11 
blood thinners and  
anticoagulants 538 1.78 968 1.86 7,207 1.96 
calcium channel blockers 2,876 9.50 5,298 10.16 35,658 9.69 
cardioselective beta blockers 1,405 4.64 2,229 4.28 14,101 3.83 
diuretics 4,399 14.53 7,324 14.05 66,953 18.20 
cholinergics 12 0.04 16 0.03 184 0.05 
hormone replacement therapy 923 3.05 1,100 2.11 14,562 3.96 
fibrates 2,668 8.81 3,462 6.64 23,955 6.51 
niacin 607 2.01 905 1.74 6,533 1.78 
nitrates 217 0.72 482 0.92 2,975 0.81 
NSAIDs 5,844 19.31 8,935 17.14 83,764 22.77 
bronchodilators 3,123 10.32 4,195 8.05 43,808 11.91 
inhaled steroids 4,830 15.96 6,603 12.66 70,760 19.23 
oral corticosteroids 6,421 21.21 9,127 17.51 90,048 24.48 
erythropoietan 6 0.02 22 0.04 22 0.01 
ophthalmic drugs 618 2.04 1,000 1.92 6,262 1.70 
disease-modifying  
antirheumatic drugs  543 1.79 882 1.69 6,891 1.87 
biologic response modifiers 171 0.56 259 0.50 1,930 0.52 
peripheral neuropathic  
treatments 1,265 4.18 1,474 2.83 14,991 4.07 
statins 12,852 42.46 19,534 37.47 139,601 37.94 




Table 2. Incidence rates of primary composite outcome, acute myocardial infraction, 










Outcome 450 910 5,445 
Total person years 20,982 36,595 309,151 
Rate per 1,000 person  
years 21.45 24.87 17.61 
Median [IQR]  
observation time, days 187 [107, 314] 173 [104, 317] 225 [134, 384] 
Rate difference (95%  
CI) -- -3.42 [-5.98, -0.86] 3.83 [1.80, 5.87] 
Acute Myocardial 
Infarction 52 138 791 
Total person years 21,236 37,060 312,411 
Rate per 1,000 person  
years 2.45 3.72 2.53 
Median [IQR]  
observation time, days 189 [108, 317] 176 [104, 321] 227 [135, 388] 
Rate difference (95%  
CI) -- -1.28 [-2.19, -0.36] -0.08 [-0.77, 0.61] 
Stroke 47 151 786 
Total person years 21,239 37,027 312,438 
Rate per 1,000 person  
years 2.21 4.08 2.52 
Median [IQR]  
observation time, days 189 [108, 317] 175 [104, 321] 227 [135, 388] 
Rate difference (95%  
CI) -- -1.87 [-2.77, -0.86] -0.07 [-0.76, 0.62] 
Heart Failure 47 149 602 
Total person years 21,238 37,052 312,548 
Rate per 1,000 person  
Years 2.21 4.02 1.93 
Median [IQR]  
observation time, days 189 [108, 317] 175 [104, 321] 227 [135, 388] 
Rate difference (95%  
CI) -- -1.81 [-2.71, -0.90] 0.52 [-0.16, 1.21] 
1 Primary composite outcome includes myocardial infarction, cardiac arrest, coronary  
   artery bypass, coronary angioplasty, heart failure, stroke, death 
2 Incidence rate difference per 1,000 person-years 




Table 3. Hazard ratios for the association between DPP-4 inhibitor use and primary composite outcome, acute myocardial 
infraction, stroke, and heart failure compared to Sulfonylureas and Metformin 





Infarction Stroke Heart Failure 
Sulfonylureas         
  HR [95% CI]1 0.86 [0.77, 0.97] 0.69 [0.50, 0.95] 0.54 [0.39, 0.75] 0.58 [0.42, 0.81] 
  aHR [95% CI]2 0.87 [0.78, 0.98] 0.70 [0.51, 0.96] 0.57 [0.41, 0.79] 0.57 [0.41, 0.79] 
Metformin 
 
      
  HR [95% CI]1 1.08 [0.98, 1.19] 0.91 [0.69, 1.21] 0.80 [0.59, 1.07] 1.05 [0.78, 1.41] 
  aHR [95% CI]2 1.07 [0.97, 1.18] 0.95 [0.72, 1.27] 0.81 [0.60, 1.09] 1.04 [0.77, 1.40] 
1 Propensity score weighting only 
2 Propensity score weighting, spline terms for cumulative exposure, and demographics, comorbidities, and concomitant 
medications as regressors and stratifiers 
3 Primary composite outcome includes myocardial infarction, cardiac arrest, coronary artery bypass, coronary angioplasty, heart 



















eTable 1. Categorization of drugs into exposure groups 
 
FDA Approved DPP-4 Inhibitors  
alogliptin 
alogliptin and metformin 
alogliptin and pioglitazone 
linagliptin 
linagliptin and empagliflozin 
linagliptin and metformin 
linagliptin and metformin extended release 
sitagliptin 
sitagliptin and metformin 
sitagliptin and metformin extended release 
saxagliptin 
saxagliptin and metformin extended release 
 
FDA Approved Sulfonylureas  
chlorpropamide 
glimepiride 
glimepiride and pioglitazone hydrochloride 
glimepiride and rosiglitazone maleate 
glipizide 
glipizide extended release 
glyburide 




FDA Approved Biguanides  
metformin hydrochloride 




eTable 2. Covariates used in propensity score model and adjusted Cox 





Included in adjusted 
Cox PH Model 
   
Covariate Stratifier 
Demographics 
    Male X X 
 
X 
Age X X 
 
X 
Location (Region) X 
   
     Cumulative Exposure X 
  
X 
     Comorbidities in Baseline 
    Asthma X X 
  Peripheral vascular  
disease X X 
  Ischemic heart disease X 
   Hypertension X X X 
 Retinopathy X X 
  Eye disease X X X 
 Renal disease X 
 
X 
 Atrial fibrilation X 
   Neuropathy X X X 
 Nephropathy X 
   aDCSI Score X 
   
     Dual Exposures 
  
X 
 Sulfonylureas X 
 
X 
 Metformin X 
 
X 
 DPP-4 inhibitors X 
   
     Concomitant Medications 
at Baseline 
    ACE inhibitors X X 
  alpha agonists X 
   analgesics X 
   angiotensin II receptor  
blockers X X X 
 anti Veg-F X 
   anticoagulants X 
   antidepressants X X 






eTable 2 (cont'd). Covariates used in propensity score model and adjusted Cox 





Included in adjusted 
Cox PH Model 
   
Covariate Stratifier 
Concomitant Medications at 
Baseline 
    aspirin X    
benzodiazepines X X X 
 beta blockers X X 
 
X 
beta blockers (ophthalmic) X 
   bile acid sequestrants X 
   biologic response modifiers X 




bronchodilators X X 
 
X 
calcium channel blockers X X X 
 carbonic anhydrase inhibitors X 
   cardioselective beta blockers X X 
  cholinergics X 
   disease-modifying  
antirheumatic drugs  X X 
  diuretics X X 
  erythropoietan X 
   fibrates X X 
  hormone replacement therapy X X 
  inhaled steroids X X 
 
X 
leukotrine modifiers X 
   loop diuretics X 
   MAOI X 
   niacin X 
   nitrates X 
   NSAIDs X X 
 
X 
ophthalmic drugs X 
   oral corticosteroids X X 
  other asthma medication X 
   peripheral neuropathic  
treatments X X X 
 phosphodiesterase-4  
inhibitors X 
   potassium sparing diuretics X 
   prostaglandins X 
   SNRI X 




eTable 2 (cont'd). Covariates used in propensity score model and adjusted Cox 





Included in adjusted 
Cox PH Model 




    SSRI X    
statins X X X  
theophyllines X 
   thiazide diuretics X X X 
 tricyclic antidepressants X 
   vasodilators X 
   α-Glucosidase inhibitors X 
    
 
 
eTable 3. Hazard ratios for the association between DPP-4 inhibitor use and 
primary composite outcome, showing sensitivity to individuals with more than one 
exposure group 
  Hazard Ratios for DPP-4 Inhibitors Use 
Reference Drug 
Allowing for dual 
exposure 
Disallowing dual exposure 
Sulfonylureas     
HR (95% CI)1 0.86 [0.77, 0.97] 0.86 [0.76, 0.96] 




HR (95% CI)1 1.08 [0.98, 1.19] 1.10 [1.00, 1.21] 
aHR (95% CI)2 1.07 [0.97, 1.18] 1.10 [1.00, 1.21] 
1 Propensity score weighting only 
2 Propensity score weighting, spline terms for cumulative exposure, and demographics, 






eTable 4. Hazard ratios for the association between DPP-4 inhibitor use and 
primary composite outcome, showing sensitivity to latency after drug 
discontinuation 
  Hazard Ratios for DPP-4 Inhibitors Use 
Reference Drug 14-day lag censor 7-day lag censor 
30-day lag 
censor 
Sulfonylureas       
HR (95% CI)1 0.86 [0.77, 0.97] 0.85 [0.75, 0.96] 0.86 [0.77, 0.96] 
aHR (95% CI)2 0.87 [0.78, 0.98] 0.85 [0.76, 0.96] 0.87 [0.78, 0.97] 
Metformin 
 
    
HR (95% CI)1 1.08 [0.98, 1.19] 1.07 [0.96, 1.18] 1.07 [0.98, 1.18] 
aHR (95% CI)2 1.07 [0.97, 1.18] 1.09 [0.98, 1.21] 1.11 [1.01, 1.21] 
1 Propensity score weighting only 
2 Propensity score weighting, spline term for cumulative exposure, and demographics, 




eTable 5. Weighted and unweighted hazard ratios for the association between 
DPP-4 inhibitor use and primary composite outcome 
  Hazard Ratios for DPP-4 Inhibitors Use 
Reference Drug Hazard Ratio [95% CI] 
Sulfonylureas   
Unweighted HR (95% CI)2 0.87 [0.78, 0.97] 
HR (95% CI)3 0.86 [0.77, 0.97] 
aHR (95% CI)4 0.87 [0.78, 0.98] 
Metformin   
Unweighted HR (95% CI)2 1.10 [1.00, 1.21] 
HR (95% CI)3 1.08 [0.98, 1.19] 
aHR (95% CI)4 1.07 [0.97, 1.18] 
1 Primary composite outcome includes myocardial infarction, cardiac arrest, coronary 
artery bypass, coronary angioplasty, heart failure, stroke, death 
2 Adjusted for demographics, comorbidities, and concomitant medications 
3 Propensity score weighting only 
4 Propensity score weighting, spline term for cumulative exposure, and demographics, 





eTable 6. Pre- and Post-weighting distribution of covariates across exposure groups 
 
 
eTable 6. Pre- and Post-weighting distribution of covariates across exposure groups 
  DPP4i Sulfonylureas Metformin 
    Pre-weighting Post-weighting Pre-weighting Post-weighting 
  Mean Mean p-value Mean p-value Mean p-value Mean p-value 
Male 0.57 0.58 <0.01 0.57 0.96 0.51 <0.01 0.57 0.83 
Age 0.18 0.18 <0.01 0.18 0.91 0.22 <0.01 0.18 0.98 
Region 0.19 0.14 <0.01 0.19 1.00 0.15 <0.01 0.19 1.00 
Peripheral vascular 
disease 0.97 0.98 <0.01 0.97 0.80 0.98 <0.01 0.97 0.84 
Asthma 0.94 0.95 <0.01 0.94 0.89 0.93 <0.01 0.94 0.87 
Eye disease 0.74 0.77 <0.01 0.74 0.77 0.77 <0.01 0.74 0.94 
Hypertension 0.38 0.41 <0.01 0.37 0.74 0.41 <0.01 0.38 0.84 
Neuropathy 0.92 0.93 <0.01 0.92 0.92 0.92 0.83 0.93 0.76 
Retinopathy 0.95 0.95 0.01 0.95 0.90 0.97 <0.01 0.95 0.87 
Benzodiazepine 0.89 0.91 <0.01 0.89 0.96 0.87 <0.01 0.89 0.75 
Fibrates 0.91 0.93 <0.01 0.91 0.91 0.93 <0.01 0.91 0.84 
Antidepressants 0.97 0.98 <0.01 0.97 0.99 0.96 <0.01 0.97 0.81 
Oral corticosteroids 0.79 0.82 <0.01 0.79 0.85 0.76 <0.01 0.79 0.76 
Inhaled steroids 0.84 0.87 <0.01 0.84 0.83 0.81 <0.01 0.84 0.80 
Bronchodilators 0.90 0.92 <0.01 0.90 0.94 0.88 <0.01 0.90 0.91 
ACE inhibitors 0.81 0.78 <0.01 0.81 0.92 0.77 <0.01 0.81 0.80 
Antiplatelets and 
blood thinners 0.88 0.90 <0.01 0.88 0.93 0.87 <0.01 0.88 0.77 
Hormone 
replacement therapy 0.97 0.98 <0.01 0.97 0.91 0.96 <0.01 0.97 0.82 
NSAIDs 0.81 0.83 <0.01 0.81 0.74 0.77 <0.01 0.81 0.83 
Angiotensin II 
receptor blockers 0.78 0.84 <0.01 0.78 0.95 0.84 <0.01 0.78 0.79 
Beta blockers 0.86 0.85 <0.01 0.86 0.87 0.84 <0.01 0.86 0.79 
Cardioselective beta 
blockers 0.95 0.96 0.01 0.95 0.90 0.96 <0.01 0.95 0.90 
Diuretics 0.15 0.14 0.05 0.15 0.90 0.18 <0.01 0.15 0.97 
Statins 0.58 0.63 <0.01 0.58 0.94 0.62 <0.01 0.58 0.98 
Peripheral 
neuropathic agents 0.96 0.97 <0.01 0.96 0.95 0.96 0.38 0.96 0.80 
Calcium channel 
blockers 0.90 0.90 <0.01 0.90 0.88 0.90 0.28 0.90 0.76 
Disease-modifying 
antirheummatic 
agents 0.98 0.98 0.28 0.98 0.84 0.98 0.33 0.98 0.84 
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Purpose: Cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among 
high-risk patients, such as those with established cardiovascular or kidney disease, is 
poorly understood.  These individuals make up a fraction of new users of 
antihyperglycemic agents; however, their comorbidities increase their underlying 
cardiovascular risk, potentially confounding the relationship between DPP-4i use and 
major adverse cardiovascular events (MACE).  In this study, we investigated the risk of 
MACE associated with the use of DPP-4i among individuals with diabetes, comorbid 
with cardiovascular disease, chronic kidney disease, and/or acute renal impairment.   
 
Methods: Using a retrospective, new-user, cohort design, we analyzed Truven 
Marketscan Commercial Claims and Encounters from 2010-2015.  We studied 
commercially-insured patients with diabetes, comorbid with cardiovascular disease 
and/or renal impairment to determine the association between DPP-4i and MACE.  We 
compared outcomes with use of DPP-4i to sulfonylureas and to metformin using a 
propensity score weighted Cox proportional hazards model, adjusting for demographics, 
baseline comorbidities and concomitant medications. Additionally, we separately 
assessed the association between DPP-4i and heart failure, acute myocardial infarction, 
and stroke.   
 
Results: In our cohort of 113,296 individuals, 8.1% used DPP-4i, 15.4% used 
sulfonylurea, and 78.2% used metformin. MACE incidence with DPP-4i was less than 
with sulfonylurea (-30.20 per 1,000 person-years; IQR [-40.5, -19.9]) and comparable to 
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that with metformin (7.75 per 1,000 person-years; IQR: [-0.5, 16.0]).  After adjustment, 
DPP-4i were associated with a lower risk of MACE than sulfonylurea (aHR=0.84; 95% 
CI: [0.7, 0.9]); similar to that with metformin (aHR=1.07; 95% CI: [1.0, 1.2]).  No 
significant associations were seen in the secondary outcomes after adjustment. 
 
Conclusions: Among high-risk patients, DPP-4i were associated with a lower risk of 
MACE than sulfonylureas, with MACE hazards comparable to that with metformin use.  
 
Keywords 
Dipeptidyl peptidase-IV inhibitors; drug-related side effects and adverse reactions; major 





Diabetes afflicts nearly 26 million people in the United States, who often have 
very high morbidity and mortality1,2.  Individuals with diabetes have high rates of 
cardiovascular disease (CVD)3, including peripheral arterial disease and cerebrovascular 
disease, and treatment choices need to be made in light of these serious and prevalent 
comorbidities. 
 
One important class of medicines to treat Type 2 diabetes are the dipeptidyl 
peptidase-IV inhibitors (DPP-4i); these drugs slow the breakdown of GLP-1, inhibiting 
glucagon release and increasing insulin release4.  Five medications in this class have been 
approved by the FDA since 2006, for use alone or in combination, and they rank third in 
utilization after biguanides and sulfonylurea with 8% of antidiabetic drug prescriptions5. 
 
DPP-4i(s) were initially believed to be protective against major adverse 
cardiovascular events (MACE), evidenced through pre-approval clinical trials6.  Given 
high rates of cardiovascular disease among diabetics7,8, as well as longstanding regulatory 
interest in the potential adverse cardiovascular events associated with diabetes 
treatments9, evidence of such a cardioprotective effect would be of high regulatory, 
clinical and marketing importance.  However, despite this early evidence from pre-
approval studies, postmarketing surveillance reports10,11 and data from Phase 4 clinical 




In this retrospective study, we focused on patients at elevated baseline risk, 
specifically those with history of cardiovascular disease and/or renal disease (i.e. chronic 
kidney disease and acute kidney impairment), comparing the rates of adverse 
cardiovascular events among DPP-4i users with that of comparable users of metformin 
and sulfonylurea.  Our inclusion of patients with renal disease stemmed from results of 
the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes 
Mellitus Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial, which 
showed that renal disease was independently associated with increased risk for MACE15.  
We were interested in this elevated risk population, because if a discernable effect were 




Study Design and Data Source 
We conducted a population-based, retrospective cohort with a new user design 
using data from Truven Health MarketScan Commercial Claims and Encounters from 
January 2010 through December 2015.  MarketScan houses linked paid claims and 
encounter data from approximately 350 payers, covering more than 25 million 
individuals annually.  The data consists of de-identified individual-level healthcare 
utilization data including demographic characteristics and information on inpatient and 







We included individuals with type 2 diabetes having at least one prescription for 
an oral antihyperglycemic agent and either HbA1c greater than 6.5% twice, fasting 
glucose greater than 126 mg/dL twice on different days, random glucose > 200 mg/dL 
twice on different days, one inpatient diagnosis of for diabetes (ICD-9(10): 250x (E11.9), 
357.2 (E11.42), 366.41 (E11.36), 362.01-362.07 (E11.3*)) or outpatient diagnosis for 
diabetes (ICD-9(10): 250x (E11.9), 366.41 (E11.36), 362.01-362.07 (E11.3*)) twice on 
different days.  For inclusion, individuals needed to have filled at least one prescription 
for a DPP-4i, a sulfonylurea, or metformin (eTable 1).  We assigned an index date as the 
date of the first filled prescription for one of these products, and the baseline period was 
defined as the preceding six-month period. We used International Classification of 
Diseases, 9th and 10th Revisions (ICD-9/10) codes (eTable 2) from inpatient and 
outpatient records to identify those with a history of cardiovascular disease and/or renal 
impairment for inclusion into the study.   
 
We excluded individuals based on: 1) without continuous medical or pharmacy 
enrollment in the six-month baseline period; 2) below the age of 35; 3) with insulin use 
during the baseline period; 4) patients on dialysis in the baseline period; 5) less than 12-
weeks of exposure to index treatment; or 6) treatment with other oral antihyperglycemic 
agents in the baseline period.  We followed patients until the first of either: date of major 
adverse cardiovascular event or censoring at 14-days after the last date of exposure, 
switch in anti-hyperglycemic treatment or addition of another anti-hyperglycemic agent, 




Definition of Exposure 
We assigned patients to an exposure group based on their first prescription of 
DPP-4i, sulfonylurea, or metformin.  In the event of multiple drug class prescriptions on 
the index date, patients were counted in all relevant exposure groups.  
 
Definition of Outcome 
We defined our primary composite outcome as the first of any of the following 
events: myocardial infarction, cardiac arrest, coronary artery bypass graft, coronary 
angioplasty, heart failure, or stroke.  Our secondary outcomes were acute myocardial 
infarction, stroke, and heart failure.  We used validated algorithms to identify myocardial 
infarction16, cardiac arrest17, coronary artery bypass graft16, coronary angioplasty16, heart 
failure18, and stroke19.  For conditions/procedures without validated ICD-10 algorithms, 
we deferred to the Chronic Conditions Warehouse20.  
 
Definition of Covariates 
We used the peer-reviewed literature21-24, clinical guidelines25-29 and expert 
opinion9,30 in order to identify key covariates of interest (eTable3).  We assessed possible 
confounding due to patient age and sex; cardiovascular risk factors including 
hypertension and hypercholesterolemia, diabetic complications, diabetic severity as 
measured by the Adjusted Diabetes Comorbidities Severity Index (aDCSI)31-33, and other 
common comorbidities such as cerebrovascular disease, ischemic heart disease, asthma, 
and rheumatoid arthritis.  Comorbidities coded under ICD-9 were identified using the 
 
 96 
Clinical Classification Software (CCS) developed by the Agency for Healthcare Research 
and Quality34.  As CCS was not updated with ICD-10 codes at the time of analysis, we 
cross-referenced these ICD-9 codes with their ICD-10 equivalents.  Additionally, we 
used National Drug Codes to assess for possible confounding due to concomitant 
medications including statins, angiotensin converting enzymes (ACE) inhibitors, platelet 
aggregation inhibitor, calcium channel blockers, angiotensin II receptor blockers, beta-
blockers, diuretics, nitrates, and inhaled corticosteroids.  
 
Propensity Score 
We used the Toolkit for Weighting and Analysis of Nonequivalent Groups 
(twang) package developed by the RAND Corporation35 to compute the propensity scores 
and associated weights used in the analysis to balance the covariates between exposure 
groups.  To do so, we identified all available covariates with an association to the primary 
outcome but without an association to the exposure in order to increase precision36.  Next, 
we used generalized boosted regression models to optimize the selection of covariates for 
the propensity score calculation.  The twang package allows for propensity scores 
estimation in the presence of multiple exposure groups.  We used the standardized mean 
difference (SMD) to measure balance of covariates before and after weighting.  
Propensity score weighting reduced the SMD from a maximum of 0.23 to less than 0.01 
(eFigure 2).  We used the average treatment effect on the treated (ATT) propensity score 






Using chi-square statistics for categorical covariates and the Kruskal-Wallis test 
for continuous covariates, we compared differences at baseline between new users of 
DPP-4i, sulfonylurea, and metformin.  We used exact Poisson tests to compare absolute 
differences in incidence rates for the primary and secondary outcomes for new users of 
DPP-4i compared to those of sulfonylurea and metformin.  Additionally, we checked for 
differences in time-to-event distributions using a Kolmogorov-Smirnov test.  Using the 
propensity score weights described above, we calculated weighted crude and adjusted 
Cox proportional hazards for the association between new use of DPP-4i and the primary 
and secondary outcomes compared to new use of sulfonylureas and metformin.  For the 
adjusted hazard ratios, we included indicators for age, sex, cumulative exposure, baseline 
comorbidities, and concomitant medication (eTable 3).  Additionally, we checked for 
covariates that violated the proportional hazards assumption by plotting the scaled 
Schoenfeld residuals.  We stratified the Cox proportional hazards model by these 
covariates.  We also used spline terms for cumulative exposure.  Finally, we included an 
indicator for individuals included in multiple exposure groups.  All analyses were 
conducted in R, version 3.3.3. 
 
Sensitivity Analyses 
To check the robustness of our results, we first assessed possible sensitivity of our 
results to the latency of the period after drug discontinuation.  We followed patients for 
14-, 7-, and 30-days after the last day of exposure to drug.  Next, we recalculated the 
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primary analysis without patients with acute renal failure at baseline to determine 
whether our results were sensitive to the inclusion of those patients.  
 
The study was exempted from review by the appropriate Johns Hopkins 




Subject Inclusion and Characteristics 
We identified 12,166,812 individuals with diabetes from 2010-2015.  After 
applying our inclusion and exclusion criteria, there were 113,296 individuals in our 
cohort (Figure 1).  Of these, 9146 (8.1%) were new users of DPP-4i, 17481 (15.4%) 
initiated sulfonylureas, and 88596 (78.2%) started metformin.  Three percent of included 
patients were new users of both DPP-4i and metformin, and 1,524 (1.3%) were new users 
of both sulfonylureas and metformin.   
 
More sulfonylurea users (60.4%) were male compared to DPP-4i (58.5%) or 
metformin (52.2%) users. (Table 1) Approximately half of patients in each exposure 
group had a cumulative exposure to the treatment of interest less than or equal to 6 
months (DPP-4i: 54.0%; sulfonylureas: 56.3%; metformin: 53.7%).  Rates of 
cardiovascular disease were higher among users of metformin than their counterparts, 
while kidney disease was more prevalent among users of sulfonylureas (17.2%) and 
DPP-4i (15.0%) than metformin (7.1%). Differences between users of DPP-4i, 
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sulfonylurea, and metformin diminished after application of propensity score weighting 
(eTable 4). 
 
Association between treatment and major adverse cardiovascular events (MACE) 
The median time until the primary outcome was 160 days (interquartile range 
[IQR] 92- 296 days) and there was no statistically significant difference in time-to-event 
distributions across the therapeutic classes examined (eFigure 2).  After propensity score 
weighting and adjusting for baseline demographics, clinical characteristics, and 
concomitant medications, the incidence rate for the primary outcome was statistically 
significantly lower, by 30.2 per 1000 person-years, among new users of DPP-4i 
compared to sulfonylureas (Table 2).  There was a non-statistically significant increase in 
the incidence rate for the primary outcome among new users of DPP-4i’s compared to 
metformin (91.25 per 1,000 person-years vs. 79.46 per 1,000 person-years).  Among the 
secondary outcomes, the incidence rate for heart failure was significantly less (4.07 per 
1,000 person-years vs. 7.56 per 1,000 person-years) for new users of DPP-4i compared to 
sulfonylurea.  The incidence rates for the secondary outcomes were not significantly 
different between DPP-4i and metformin.   
 
After propensity score weighting and adjustment for baseline demographics, 
clinical characteristics, and concomitant medications, the risk of MACE was less with 
new use of DPP-4i compared to with new use of sulfonylurea (adjusted hazard ratio 
[aHR] 0.84, 95% confidence interval [CI] 0.7-0.9).  There was not a statistically 
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significant difference in risk of MACE with DPP-4i as compared with metformin (aHR 
1.07, CI 1.0-1.2) (Table 3).   
 
There was a statistically significant association for heart failure in the propensity 
score weighted analysis comparing DPP-4i to sulfonylurea (HR 0.95, CI [0.4-0.9); 
however, after adjusting for potential confounders, the association was attenuated and no 
longer statistically significant.  DPP-4i was also not statistically significantly associated 
with acute myocardial infarction when compared to sulfonylureas (aHR 0.95, CI 0.7-1.4) 
or metformin (aHR 1.32, CI 1.0-1.2), nor was there a statistically significant association 
between DPP-4i and stroke when compared to sulfonylureas (aHR 1.08, CI 0.9-1.4) or 
metformin (aHR 1.16, CI 1.0-1.4).  
 
Sensitivity Analyses 
Results of analyses excluding patients with acute renal failure showed 
qualitatively similar results to those including these patients (eTable 6).  Similarly, 
results were not sensitive to changes in the latency period after the last dose of exposure 
for the primary analysis results, nor did they differ substantively when lagging the latency 




In this longitudinal study of commercial claims data for patients with diabetes, 
comorbid with cardiovascular disease and/or renal disease, new use of DPP-4i was 
associated with less risk for MACE compared to sulfonylureas, and a comparable risk 
 
 101 
compared to metformin.  New use of DPP-4i was not shown to be associated with the 
following individual components of MACE: heart failure, stroke, or acute myocardial 
infarction.  These results expand upon the body of evidence examining the association of 
DPP-4i and MACE in patients at higher risk for cardiovascular events.   
 
Overall, our results corroborated those of previous clinical trials and observational 
studies of cardiovascular safety of DPP-4i.  Our analysis detected no increased risk for 
MACE with the use of DPP-4i similar to the conclusions in the three completed clinical 
trials comparing DPP-4i and placebo12,13,37.  Unlike these trials however, our study 
population consisted of a high-risk group of patients in a real-world setting with multiple 
comorbidities and concomitant medications.  Additionally, our study allowed us to 
compare DPP-4i to other available therapies, namely sulfonylureas and metformin, 
showing a decreased risk for MACE when compared to sulfonylureas.   
 
Three notable observational studies provide additional context to our results.  
First, a 2015 administrative claims study of patients with diabetes and chronic kidney 
disease admitted for acute myocardial infarction in the Taiwan National Health Insurance 
Research Database also showed no increased risk for MACE when comparing patients on 
sitagliptin to those not on sitagliptin24.  Expanding on this approach, our study design 
included patients with a host of cardiovascular conditions at baseline, making our results 
more generalizable to high-risk patients with diabetes.  The second study of 127,555 
patients in the Italian Nationwide OsMed Health-DB database showed decreased risk in 
hospitalization for heart failure risk associated with DPP-4i compared to sulfonylurea 
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(HR=0.78; 95% CI: [0.62, 0.97])38.  This suggests that the increased risk for MACE in 
our comparison might be driven by differences in risk for heart failure.  This is partially 
evident in the statistically significant unadjusted hazard ratio for heart failure as a 
secondary outcome (Table 3).  Finally, a study of Medicare patients with diabetes 
compared cardiovascular risk of DPP-4i to sulfonylurea and thiazolidinediones and found 
no increased risk in patients over age 6539.  While our study was limited to a patient 
population under age 65, our results are similar to those found in a study of older patients.   
 
A major strength of our study is the identification of a high-risk cohort through 
the use of a large administrative database.  The results of the SAVOR TIMI-53 trial 
suggested that renal impairment was independently associated with adverse 
cardiovascular outcomes, even after adjusting for cardiovascular risk factors15.  As such, 
our decision to restrict the study cohort to patients with diabetes, comorbid with 
cardiovascular disease and renal impairment allowed us to hone in on a patient 
population identified by FDA as more appropriate for the study of this drug-event 
association.  In a 2008 Guidance for Industry9, regulators noted that such patients are 
often excluded from pre-approval clinical trials, and recommended studies of the 
association between oral antihyperglycemic agents and MACE should include high-risk 
patients.   
 
Our study also had limitations.  First, we included patients using multiple 
therapies of interest (e.g., both DPP-4i and sulfonylureas) at baseline.  While this may 
have led to potential misclassification, their exclusion would have resulted in a much 
 
 103 
smaller and less generalizable sample 40.  Second, our new user design did not account 
for time-varying hazards for MACE. We partially addressed this by including spline 
terms for cumulative exposure to account for changes in baseline hazard.  Third, our 
analyses are subject to potential informative censoring due to a change in exposure status.  
However, our results were insensitive to the lagged latency period after the last day of 
exposure, and since most events occurred within the first year of exposure, extending the 
latency period past 30-days would have been unlikely to have changed our results and 
could have potentially led to misclassification. Finally, we were unable to assess 
mortality as a component of the primary composite outcome or as a competing risk due to 




Our results provide evidence of decreased risk for MACE when comparing DPP-
4i versus sulfonylurea in a commercially insured patient population with diabetes, 
comorbid with cardiovascular disease and renal impairment in the United States.  
Additionally, we found that there was no difference in risk of MACE for these patients 
when comparing DPP-4i and metformin.  Further studies are needed to determine 
differences in risk for individual components of the composite outcome, particularly heart 
failure.  Finally, the decreased risk seen with DPP-4i use compared to sulfonylurea is 
more likely due to cardiovascular risk associated with sulfonylurea rather than protective 
effects of DPP-4i, as there was no difference in effect between DPP-4i and metformin, 
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TABLES AND FIGURES 
 
Figure 1. Cohort derivation and sample attrition 
 
1 OHA = oral antihyperglycemic agents     2 Subcategories are not mutually exclusive
Diabetic Patients in Truven Marketscan 2010-15 
(N=12,166,812) 
Total patients exposed to DPP-4i, Sulfonylurea, or Metformin 
(N=2,741,571) 
Total excluded for pre-defined criteria 
(N=1,969,032)2  
   - <6mo enrollment in baseline:    
      1,216,312 
   - Insulin users: 545,836 
   - Under age 35: 206,884 
Total patients exposed to DPP-4i, Sulfonylurea, or Metformin after application of 
exclusion criteria 
(N=772,540) 
Total excluded for no cardiovascular 
disease or renal impairment at baseline 
(N=659,244) 
Total patients exposed other OHA1 
(N=9,425,241) 
Total patients exposed to DPP-4i, Sulfonylurea, or Metformin with cardiovascular disease 
and renal impairment at baseline 
(N=113,296) 
 
   - DPP-4i (n=9,146) 
   - Sulfonylurea (n=17,481) 












  N % N % N % 
Male sex 5,351 58.5 10,559 60.4 46,224 52.2 
Age, years 
       35-44 877 9.6 2,066 11.8 11,755 13.3 
    45-54 2,815 30.8 5,147 29.4 29,238 33.0 
 55-64 5,454 59.6 10,268 58.7 47,603 53.7 
  
      Cumulative Exposure, months 
       <6 months 4,943 54.0 9,838 56.3 47,534 53.7 
 6-12 months 2,580 28.2 4,326 24.7 23,869 26.9 
 12-18 months 848 9.3 1,665 9.5 8,713 9.8 
 >18 months 775 8.5 1,652 9.5 8,480 9.6 
  
      Comorbidities in Baseline 
      Cardiovascular disease 8,187 89.5 15,359 87.9 84,138 95.0 
Kidney disease (chronic and acute) 1,372 15.0 3,011 17.2 6,263 7.1 
Cerebrovascular disease 1,574 17.2 2,931 16.8 14,391 16.2 
Ischemic heart disease 3,926 42.9 7,374 42.2 35,242 39.8 
Hypertension 7,501 82.0 13,902 79.5 68,723 77.6 
Eye disease 3,149 34.4 5,289 30.3 28,809 32.5 
Renal disease1 4,029 44.1 7,243 41.4 34,718 39.2 
Acute renal failure 465 5.1 1,126 6.4 2,118 2.4 
Neuropathy 1,320 14.4 2,270 13.0 12,573 14.2 
Nephropathy 559 6.1 1,330 7.6 2,455 2.8 
aDCSI2 Score 
         0 5,813 63.6 11,326 64.8 61,295 69.2 
   1 1,203 13.2 2,055 11.8 10,806 12.2 
   2 1,358 14.8 2,738 15.7 11,290 12.7 
   3+ 772 8.4 1,362 7.8 5,205 5.9 
1 Includes diseases of kidneys, ureters, and bladders; inclusive of acute renal failure.  












  N % N % N % 
Dual Exposures 
      Sulfonylureas 0 0.0 0 0.0 1,524 1.7 
Metformin 3,451 37.7 1,524 8.7 0 0.0 
DPP-4 inhibitors 0 0.0 0 0.0 3,451 3.9 
  
      Concomitant Baseline Medications  
      ACE inhibitors 2,022 22.1 3,643 20.8 20,522 23.2 
Angiotensin II receptor blockers 2,380 26.0 3,346 19.1 18,410 20.8 
Antidepressants 2,132 23.3 3,378 19.3 24,832 28.0 
Antiplatelets 2,871 31.4 4,729 27.1 28,182 31.8 
Asthma medication 4,599 50.3 7,531 43.1 48,709 55.0 
Benzodiazepines 1,842 20.1 2,905 16.6 20,485 23.1 
Beta blockers 2,832 31.0 5,208 29.8 28,437 32.1 
Blood thinners and anticoagulants 496 5.4 820 4.7 4,924 5.6 
Calcium channel blockers 1,507 16.5 2,762 15.8 13,754 15.5 
Cardioselective beta blockers 940 10.3 1,632 9.3 7,767 8.8 
Diuretics 1,737 19.0 3,016 17.3 19,258 21.7 
Nitrates 807 8.8 1,342 7.7 7,924 8.9 
Peripheral neuropathic treatments 688 7.5 944 5.4 6,867 7.8 
Statins 4,699 51.4 7,484 42.8 41,933 47.3 





Table 2. Incidence rates of primary composite outcome, acute myocardial infraction, 











Outcome 510 1,301 4,781 
Total person years 5,578 10,696 57,134 
Rate per 1,000 person  
years 91.25 121.63 79.46 
Median [IQR]  
observation time, days 160 [92, 286] 144 [75, 288] 163 [93, 300] 
Rate difference (95%  
CI) - -30.20 [-40.5, -19.9] 7.75 [-0.5, 16.0] 
Acute Myocardial 
Infarction 54 132 450 
Total person years 5,898 11,487 60,159 
Rate per 1,000 person  
years 9.16 11.49 7.06 
Median [IQR]  
observation time, days 167 [98, 297] 161 [90, 308] 172 [100, 314] 
Rate difference (95%  
CI) - -2.34 [-5.5, 0.8] 1.68 [-0.9, 4.2] 
Stroke 141 268 1,202 
Total person years 5,839 11,380 59,592 
Rate per 1,000 person  
years 24.15 23.55 20.17 
Median [IQR]  
observation time, days 167 [97, 295] 159 [90, 305] 171 [99, 311] 
Rate difference (95%  
CI) - 0.60 [-4.3, 5.5] 3.98 [-0.2, 8.1] 
Heart Failure 24 87 240 
Total person years 5,912 11,512 60,277 
Rate per 1,000 person  
years 4.06 7.56 3.98 
Median [IQR]  
observation time, days 168 [98, 298] 161[90,308] 172 [100, 314] 
Rate difference (95%  
CI) - -3.50 [-5.8, -1.2] 0.08 [-1.6, 1.8] 
1 Primary composite outcome includes myocardial infarction, cardiac arrest, coronary artery bypass, 
coronary angioplasty, heart failure, stroke 
2 Incidence rate difference per 1,000 person-years 





Table 3. Hazard ratios for the association between DPP-4 inhibitor use and primary composite outcome, acute myocardial infraction, 
stroke, and heart failure compared to sulfonylureas and metformin 






Stroke Heart Failure 
Sulfonylureas         
HR (95% CI)1 0.77 [0.7, 0.9] 0.81 [0.6, 1.1] 1.03 [0.8, 1.3] 0.59 [0.4, 0.9] 
aHR (95% CI)2 0.84 [0.7, 0.9] 0.95 [0.7, 1.4] 1.08 [0.9, 1.4] 0.71 [0.4, 1.1] 
Metformin 
 
      
HR (95% CI)1 0.98 [0.9, 1.1] 1.13 [0.9, 1.5] 1.12 [0.9, 1.3] 0.94 [0.6, 1.4] 
aHR (95% CI)2 1.07 [1.0, 1.2] 1.32 [1.0, 1.8] 1.16 [1.0, 1.4] 1.19 [0.8, 1.8] 
1 Propensity score weighting only 
2 Propensity score weighting and demographics, comorbidities, and concomitant medications as regressors and stratifiers 






eTable 1. Categorization of drugs into exposure groups 
 
FDA Approved DPP-4 Inhibitors  
alogliptin 
alogliptin and metformin 
alogliptin and pioglitazone 
linagliptin 
linagliptin and empagliflozin 
linagliptin and metformin 
linagliptin and metformin extended release 
sitagliptin 
sitagliptin and metformin 
sitagliptin and metformin extended release 
saxagliptin 
saxagliptin and metformin extended release 
 
FDA Approved Sulfonylureas  
chlorpropamide 
glimepiride 
glimepiride and pioglitazone hydrochloride 
glimepiride and rosiglitazone maleate 
glipizide 
glipizide extended release 
glyburide 




FDA Approved Biguanides*  
metformin hydrochloride 
metformin hydrochloride extended release 
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eTable 2. ICD9/10 codes to identify patients with 
cardiovascular disease and renal impairment 
Criterion Codes 








































































































































































Included in adjusted 
Cox PH Model 
   
Covariate Stratifier 
Demographics 
    Male X X 
 
X 
Age X X 
 
X 
Location (Region) X 
   
     Cumulative Exposure X 
  
X 
     Comorbidities in 
Baseline 
    MACE X X X 
 Kidney disease X X X 
 Cerebrovascular  
disease X X 
 
X 
Congestive heart  
failure X 
   Ischemic heart  
disease X X X 
 Hypertension X X X 
 Retinopathy X 
   Eye disease X X X 
 Renal disease X X 
 
X 
Acute renal failure X 
   Atrial fibrilation X 
   Neuropathy X X X 
 Nephropathy X X X 
 aDCSI Score X X 
 
X 
     Dual Exposures 
    Sulfonylureas X 
   Metformin X 
 
X 







eTable 3 (cont'd). Covariates used in propensity score model and adjusted Cox 





Included in adjusted 
Cox PH Model 
   
Covariate Stratifier 
Concomitant Medications at 
Baseline 
    α-Glucosidase inhibitors X 
   ACE inhibitors X X X 
 alpha agonists X X 
  analgesics X 
   angiotensin II receptor  
blockers X X X 
 anti Veg-F X 
   anticoagulants X X 
  antidepressants X X X 
 antiplatelets X X 
 
X 
aspirin X X 
  asthma medication X X X 
 benzodiazepines X X X 
 beta blockers X X 
 
X 
beta blockers (ophthalmic) X 
   bile acid sequestrants X 
   biologic response modifiers X 
   blood thinners and  
anticoagulants X X X 
 bronchodilators X X 
  calcium channel blockers X X X 
 carbonic anhydrase  
inhibitors X 
   cardioselective beta  
blockers X X X 
 cholinergics X 
   disease-modifying  
antirheumatic drugs X 
   diuretics X X X 
 erythropoietan X X 
  fibrates X 
   GLP-1 agonists X 
   hormone replacement  
therapy X 
   inhaled steroids X X 





eTable 3 (cont'd). Covariates used in propensity score model and adjusted Cox 





Included in adjusted 
Cox PH Model 
   
Covariate Stratifier 
Concomitant Medications at 
Baseline 
    loop diuretics X X   
MAOI X X   
meglitinides X    
niacin X X 
  nitrates X X X 
 NSAIDs X 
   ophthalmic drugs X 
   oral corticosteroids X X 
  peripheral neuropathic  
treatments X X X 
 phosphodiesterase-4  
inhibitors X 
   potassium sparing  
diuretics X X 
  prostaglandins X X 
  SGLT-2 inhibitors X 
   SNRI X X 
  SSRI X X 




   thiazide diuretics X X X 
 thiazolidinediones X 
   tricyclic antidepressants X X 
  vasodilators X X 









eTable 4. Pre- and Post-weighting distribution of covariates across exposure groups 
  DPP4i Sulfonylurea Metformin 
    Pre-weighting Post-weighting Pre-weighting Post-weighting 
  
Mean Mean p-value Mean p-value Mean p-value Mean p-value 
Male 0.59 0.60 <.001 0.59 0.93 0.52 <.001 0.58 0.91 
Age Group 0.10 0.12 <.001 0.10 0.98 0.13 <.001 0.10 0.99 
Cardiovascular 
disease 0.10 0.12 <.001 0.11 0.96 0.05 <.001 0.10 0.85 
Kidney Disease 0.85 0.83 <.001 0.85 0.94 0.93 <.001 0.85 0.92 
Cerebrovascular 
disease 0.83 0.83 0.36 0.83 0.87 0.84 0.02 0.83 0.95 
Ischemic heart 
disease 0.57 0.58 0.24 0.57 0.84 0.60 <.001 0.57 0.90 
Hypertension 0.18 0.20 <.001 0.18 0.97 0.22 <.001 0.18 0.94 
Eye disease 0.66 0.70 <.001 0.66 0.87 0.67 <.001 0.66 0.95 
Renal disease 0.56 0.59 <.001 0.56 0.77 0.61 <.001 0.56 0.88 
Neuropathy 0.86 0.87 <.001 0.86 0.93 0.86 0.53 0.86 0.92 
Nephropathy 0.94 0.92 <.001 0.94 0.98 0.97 <.001 0.94 0.87 
aDCSI score 0.64 0.65 <.001 0.64 0.99 0.69 <.001 0.64 1.00 
Benzodiazepines 0.80 0.83 <.001 0.80 0.95 0.77 <.001 0.80 0.93 
Antidepressant 0.77 0.81 <.001 0.77 0.92 0.72 <.001 0.77 0.91 
ACE inhibitors 0.78 0.79 0.02 0.78 0.92 0.77 0.02 0.78 0.95 
Antiplatelets 0.69 0.73 <.001 0.69 0.91 0.68 0.41 0.69 0.94 
Angiotensin II 
receptor blockers 0.74 0.81 <.001 0.74 0.78 0.79 <.001 0.74 0.97 
Beta blockers 0.69 0.70 0.05 0.69 0.98 0.68 0.03 0.69 0.97 
Cardioprotective 
beta blockers 0.90 0.91 0.01 0.90 0.86 0.91 <.001 0.90 0.98 
Diuretics 0.81 0.83 <.001 0.81 0.94 0.78 <.001 0.81 0.92 
Nitrates 0.91 0.92 <.001 0.91 0.87 0.91 0.70 0.91 0.87 
Statins 0.49 0.57 <.001 0.49 0.87 0.53 <.001 0.49 0.88 
Peripheral 
neuropathic agents 0.92 0.95 <.001 0.93 0.87 0.92 0.44 0.93 0.89 
Calcium channel 
blockers 0.84 0.84 0.15 0.83 0.96 0.84 0.02 0.84 0.92 
Thiazide diuretics 0.79 0.81 0.01 0.79 0.95 0.76 <.001 0.79 0.86 
Asthma 
medication 0.50 0.57 <.001 0.50 0.79 0.45 <.001 0.50 0.98 
Blood thinners and 




eTable 5. Incidence rates of primary composite outcome, acute myocardial infraction, 
stroke, and heart failure among new users of DPP-4 inhibitors, sulfonylureas, and 









14-day lag censor 510 1,301 4,781 
Total person years 5,578 10,696 57,134 
Rate per 1,000 person  
years 91.25 121.63 79.46 
Median [IQR]  
observation time, days 160 [92, 286] 144 [75, 288] 163 [93, 300] 
Rate difference (95%  
CI) - -30.20 [-40.5, -19.9] 7.75 [-0.5, 16.0] 
7-day lag censor 510 1,301 4,781 
Total person years 4,593 9,044 47,268 
Rate per 1,000 person  
years 110.82 143.85 96.05 
Median [IQR]  
observation time, days 127 [78, 233] 118 [68, 237] 130 [79, 247] 
Rate difference (95%  
CI) - -32.81 [-45.2, -20.4] 9.89 [-0.2, 19.9] 
30-day lag censor 567 1,438 5,379 
Total person years 7,107 13,176 71,923 
Rate per 1,000 person  
years 79.78 109.14 74.79 
Median [IQR]  
observation time, days 207 [116, 352] 185 [90, 358] 211 [118, 381] 
Rate difference (95%  
CI) - -29.36 [-38.0, -20.7] 4.99 [-1.9, 11.9] 
1 Primary composite outcome includes myocardial infarction, cardiac arrest, coronary artery bypass, 
coronary angioplasty, heart failure, stroke 
2 Incidence rate difference per 1,000 person-years 







eTable 6. Hazard ratios for the association between DPP-4 inhibitor use and primary 
composite outcome, showing sensitivity to patients with acute renal failure at baseline 
  Hazard Ratios for DPP-4 Inhibitors Use 
Reference Drug 
Including patients with acute 
renal failure at baseline 
Excluding patients with acute 
renal failure at baseline 
Sulfonylureas     
HR (95% CI)1 0.77 [0.7, 0.9] 0.77 [0.7, 0.8] 




HR (95% CI)1 0.98 [0.9, 1.1] 0.97 [0.9, 1.1] 
aHR (95% CI)2 1.07 [1.0, 1.2] 1.08 [1.0, 1.2] 
1 Propensity score weighting only 
2 Propensity score weighting and demographics, comorbidities, and concomitant medications as 





eTable 7. Hazard ratios for the association between DPP-4 inhibitor use and primary 
composite outcome, showing sensitivity to latency after drug discontinuation 
  Hazard Ratios for DPP-4 Inhibitors Use 
Reference Drug 14-day lag censor 7-day lag censor 
30-day lag 
censor 
Sulfonylureas       
HR (95% CI)1 0.77 [0.7, 0.9] 0.78 [0.7, 0.9] 0.76 [0.7, 0.8] 
aHR (95% CI)2 0.84 [0.7, 0.9] 0.85 [0.7, 0.9] 0.81 [0.7, 0.9] 
Metformin 
 
    
HR (95% CI)1 0.98 [0.9, 1.1] 0.98 [0.9, 1.1] 0.96 [0.9, 1.0] 
aHR (95% CI)2 1.07 [1.0, 1.2] 1.09 [1.0, 1.2] 1.05 [0.9, 1.2] 
1 Propensity score weighting only 
2 Propensity score weighting and demographics, comorbidities, and concomitant medications as 




eTable 8. Weighted and unweighted hazard ratios for the association between DPP-4 
inhibitor use and primary composite outcome 
  Hazard Ratios for DPP-4 Inhibitors Use 
Reference Drug Hazard Ratio [95% CI] 
Sulfonylureas   
Unweighted HR (95% CI)2 0.81 [0.7, 0.8] 
HR (95% CI)3 0.77 [0.7, 0.9] 
aHR (95% CI)4 0.84 [0.7, 0.9] 
Metformin   
Unweighted HR (95% CI)2 1.06 [1.0, 1.2] 
HR (95% CI)3 0.98 [0.9, 1.1] 
aHR (95% CI)4 1.07 [1.0, 1.2] 
1 Primary composite outcome includes myocardial infarction, cardiac arrest, coronary artery bypass, 
coronary angioplasty, heart failure, stroke 
2 Adjusted for demographics, comorbidities, and concomitant medications 
3 Propensity score weighting only 
4 Propensity score weighting and demographics, comorbidities, and concomitant medications as 










eFigure 2. Distributions of cumulative exposure as measured in months for patients with events 






Cumulative Exposure, Median [IQR]
 DPP-4i: 55 [18, 160] 
 Sulfonylurea: 43 [14, 141] 





Public Health Implications 
 
Through our surveillance and retrospective analyses, we found evidence to 
suggest that while there was increased reporting to FDA of MACE associated with DPP-
4i use, further investigation of both low-and high-risk individuals with diabetes revealed 
that DPP-4i had lower risk for MACE compared to sulfonylureas and comparable risk for 
MACE compared to metformin.  This supports the use of DPP-4i as a safer first-line 
therapy than sulfonylurea for T2DM in both high- and low-risk individuals with <7.1% 
HbA1c1.   
Our surveillance study (Aim 1) identified additional MACE events that might 
potentially be associated with DPP-4i among high-risk individuals, namely myocardial 
infarction and cerebral infarction.  Though we were underpowered to analyze the 
association between DPP-4i and every individual component of MACE in the 
retrospective cohort study of high-risk individuals (Aim 3), we did identify acute 
myocardial infarction as a secondary outcome.  After controlling for baseline 
characteristics, we found no evidence of increased risk for acute myocardial infarction 
with DPP-4i compared to sulfonylurea or metformin.  Further research is needed to 
determine whether the increased reporting for cerebral infarction is associated with DPP-
4i use.   
While this dissertation was not designed to look at the cardiovascular safety of 
individual drugs in Aim 2 and 3, we performed signal detection for individual drugs in 
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Aim 1.  If there were a difference amongst DPP-4i, we would expect to see them between 
peptidomimetic (sitagliptin, saxagliptin) and nonpeptidomimetic (alogliptin, linagliptin) 
products.  One mechanism of action for DPP-4i is to form a covalent bond with Ser630 in 
the active site.  Peptidomemetic DPP-4i typically have greater selectivity for DPP-4i, 
whereas nonpeptidomimetic DPP-4i have poor selectivity, and are more likely to bond 
with DPP-8 or DPP-9.  This action can lead to inhibition of T-cell activation and 
proliferation2.  In turn, inhibition of TREG activation has been associated with lower 
cardioprotection3.  From our Aim 1 results however, both peptidomimetic and 
nonpeptidomimetic DPP-4i elicited cardiovascular safety signals.   
Finally, the decreased risk seen with DPP-4i use compared to sulfonylurea is 
more likely due to cardiovascular risk associated with sulfonylurea rather than protective 
effects of DPP-4i, as there was no difference in effect between DPP-4i and metformin, 
which carries little cardiovascular risk.   
The results of our study carry implications for patient care, clinician prescribing 
behavior, and regulatory actions.  This dissertation provides evidence that DPP-4i are a 
viable alternative to sulfonylureas for first-line therapy in new users of non-insulin 
antihyperglycemic drug therapy.  A 2016 meta-analysis of 179 clinical trials and 25 
observational studies examining the comparative effectiveness of monotherapy found that 
metformin carried a better cardiovascular safety profile that sulfonylurea4.  These 
findings align with the results of this dissertation, suggesting that both metformin and 
DPP-4i are safer alternatives for newly treated patients with diabetes.  Our Aim 2 and 3 
results show that for patients with different cardiovascular risk profiles, DPP-4i carry 
similar risks between high- and low-risk patients when compared to sulfonylurea and 
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metformin.  This has implications for physicians determining the best treatment for new 
patients, for whom they may not have a complete understanding of their cardiovascular 
risk.  Our results suggest that DPP-4i are a low-cardiovascular risk option, along with 
metformin, for first line treatment.  Finally, our results did not support the current FDA 
label warning for increased risk of heart failure with the use of saxagliptin or alogliptin 
among patients with high cardiovascular risk.  These results contribute to the current 
body of evidence used as regulatory guidance in evaluating the cardiovascular safety of 
DPP-4i.   
Review of Aim 1 
 
In the surveillance portion of the dissertation, we used a disproportionality 
analysis of FDA adverse event reports to detect safety signals, as measured by relative 
reporting ratios, for DPP-4i reports for MACE.  In the subset of adverse events reports 
that were generated from a group of patients with at high-risk for cardiovascular events, 
there was an increase in reporting of MACE for sitagliptin, saxagliptin, linagliptin, and 
alogliptin.  These signals suggested that even among a group of reports where one would 
expect to see high numbers of reports for these events, the DPP-4i class stood out.  Our 
results showed signals for multiple components of MACE in addition to the previously 
reported association with heart failure.   
Finally, we found that creating a subset of reports from drugs associated with 
diabetes and cardiovascular disease allowed for detection of additional MACE reporting.  
This approach contrasted with the analysis of the cardiovascular risks of DPP-4i using the 
full FAERS dataset.  In this latter analysis, only two signals were detected, whereas our 
use of the cardiovascular subset elicited 12 distinct signals.  We saw that for products 
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where there is a known association with cardiovascular events with those products (i.e. 
sulfonylureas), signal detection in the full FAERS dataset is sensitive enough to detect 
potential signals.  However, for products where association is tenuous, a subset with 
reports from a high-risk patient population may be more sensitive to capture additional 
signals for further investigation.   
Review of Aim 2 
 
In this retrospective cohort analysis of commercial claims data for individuals with 
diabetes and without a history of cardiovascular disease or chronic kidney disease, DPP-
4i use was associated with 13% lower risk of MACE compared to sulfonylureas, and a 
similar risk of MACE when compared to metformin.  Our results also showed decreased 
risk for the secondary outcomes of acute myocardial infarction, stroke, and heart failure 
when comparing DPP-4i to sulfonylurea.  Contrasting with the results of the 
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in 
Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE) 
trial5 and the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with 
Diabetes Mellitus (SAVOR-TIMI) trial6, we did not find increased risk for heart failure 
with the use of DPP-4i.  This is likely due to our study population restriction to low-risk 
individuals.  Understanding whether or not diabetic treatment in this population increases 
patient risk for MACE is critical to managing their care due to the close link between 





Review of Aim 3 
 
In this longitudinal study of commercial claims data for patients with diabetes, comorbid 
with cardiovascular disease and/or renal disease, new use of DPP-4i was associated with 
less risk for MACE compared to sulfonylureas, and a comparable risk compared to 
metformin.  New use of DPP-4i was not shown to be associated with the following 
individual components of MACE: heart failure, stroke, or acute myocardial infarction.  
These results expand upon the body of evidence examining the association of DPP-4i and 




Limitations in Aim 1 
One important limitation of the study was the nature of surveillance used by FDA to 
collect the adverse event reports that populate FAERS.  This system relies heavily upon 
spontaneous reporting from patients, providers, and patient advocates as well as required 
reporting from drug manufacturers.  Because FAERS collects data through passive 
surveillance, the number of adverse events reported to FDA potentially underestimates 
the true level of risk with drug products.  Another limitation with these data is the amount 
of missing information regarding patient medical history, concomitant medications, and 
drug manufacturer.  While the adverse event reporting form contains fields for these 
elements, they are often missing the requested data, or the information must be requested 
through the Freedom of Information Act.  This level of missing data did not allow for 




Limitations in Aims 2 and 3 
Our longitudinal analyses were limited by our decision to use first line therapies as 
comparators.  Many oral antihyperglycemic agents that qualify as first-line therapy 
are often prescribed concomitantly with a second first-line drug.  We were left to 
include individuals into more than one exposure group at baseline.  We recognized that 
this could have potentially led to misclassification8.  Excluding patients who were 
exposed to multiple drug groups of interest would have resulted in a reduced sample size, 
threatening the generalizability of our results.  As such, we assessed the sensitivity of our 
results to their inclusion and found them to be robust.   
 
Another limitation of the dataset was our inability to assess key unmeasured variables.  
The first of these was mortality, which we could not include as a component of the 
primary composite outcome or as a competing risk.  We also did not have data on body 
mass index, a correlate of cardiovascular disease.  Finally, we were unable to capture date 




We used the results of the surveillance study (Aim 1) as a hypothesis-generating 
tool to better inform the design of the retrospective cohort studies (Aim 2 and 3).  While 
prior evidence suggested that DPP-4i were associated with heart failure, we were 
interested in investigating whether or not there were additional signals for other MACE 
with distinct pathogenesis (e.g., myocardial infarction).  Our method of subsetting the 
adverse event reports to a high-risk pool of patients showed utility in identifying signals 
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for further investigation.  The cardiovascular subset allowed for greater sensitivity to 
detect signals that might have been confounded by comorbidities commonly found with 
diabetes.  Also, by restricting the Bayesian prior to adverse event reports stemming from 
a pool of patients with related illnesses, our approach reduced the level of residual 
confounding.   
Our retrospective cohort analyses benefited from many characteristics of the 
dataset, including a large, generalizable, patient population, inpatient and outpatient 
medical encounters data, linked prescription and medical encounters data, and six years 
of follow-up.  We leveraged these strengths to conduct separate analyses of high- and 
low-risk individuals with diabetes initiating treatment with DPP-4i.  This approach 
allowed us to tailor the covariates in each analysis to each study cohort, thereby 
acknowledging that baseline cardiovascular disease and renal disease may confound the 
relationship between DPP-4i and MACE.   
In conclusion, this dissertation contributes to the ongoing work investigating the 
cardiovascular risk of oral antihyperglycemic agents.  We did not find evidence of 
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# Load data frame with drugname, pt, and N 









# Original Code: 
####################################################################### 
 
# Create a data frame with the marginal probabilities for each drug-event combo 
    #signaldat <- data.frame(newdata) 
    #library(PhViD) 
    #signaldat <- as.PhViD(signaldat, MARGIN.THRES = 1) 
    #system.time(signaldat<-as.PhViD(newdata, MARGIN.THRES = 1)) 
 
# Disproportionality analysis and signal detection 
    #gps <- GPS(signaldat, RR0 = 1, MIN.n11 = 2, DECISION = 3,        
    #       DECISION.THRES = 0.05, 
    #       RANKSTAT = 1, TRONC = FALSE, TRONC.THRES = 1, 
    #       PRIOR.INIT = c(alpha1 = 0.2, beta1 = 0.06, alpha2 = 1.4, 
    #                      beta2 = 1.8, w = 0.1), PRIOR.PARAM = NULL) 
 
# Problematic error message after as.PhViD command: 






# Deconstructed Code to Compare Data With New Code: 
####################################################################### 
 















































# New function to create dataframe with drug, pt, n11, n.1, n1.  
# Effectively this function is a substitute for as.PhViD 
new_function<-function(dta){ 
  require(plyr) 
  data <- dta 
  data[, 1] <- as.factor(dta[, 1]) 
  data[, 2] <- as.factor(dta[, 2]) 
  data[, 3] <- as.double(dta[, 3]) 
   
  coln <- names(data) 
  names(data)[3] <- "n11" 
   
  cat("Summing over drugnames") 
  n1dot<-ddply(data, .(drugname), summarize, n1d=sum(n11, na.rm=T), .progress="text") 
  cat("Summing over adverse effects") 
  ndot1<-ddply(data, .(pt), summarize, nd1=sum(n11, na.rm=T), .progress="text") 
  cat("Merging...") 
  all<-merge(data, ndot1, by="pt", all=T) 
  all<-merge(all, n1dot, by="drugname", all=T) 
  colnames(all)<-c("drugname", "pt", "n11", "n.1", "n1.") 
  all<-all[order(all$drugname, all$pt),] 
  data<-as.matrix(all[,c(3,5,4)]) 
  rownames(data)<-paste0(all$drugname, " ", all$pt) 
  L<-all[,c(1,2)] 
   
  N<-sum(data[,"n11"], na.rm=T) 
   
  RES <- vector(mode = "list") 
  RES$L <- L 
  RES$data <- data 
  RES$N <- N 





newdata<-newdata[sample(1:nrow(newdata), size = round(nrow(newdata)/3)),] 
























unique_drugs[grepl("acetaminophen", unique_drugs, ignore.case=T)& 
               grepl("oxycodone", unique_drugs, ignore.case=T)] 
 







# GPS parameters according to Szarfman et al 
####################################################################### 
source("GPS_v2.R") 
gps <- GPS2(DATABASE=function_baksh,  
           RR0 = 1,  
           MIN.n11 = 1,  
           DECISION = 3,  
           DECISION.THRES = 2,  
           RANKSTAT = 2, 
           TRONC = F,  
           TRONC.THRES = 0,  
           PRIOR.INIT = c(alpha1= 0.2, beta1= 0.06, alpha2=1.4, beta2=1.8, w=0.1),  








options(max.print = 9999999) 
PhViD.search(RESULT, DRUG = NULL, EVENT = NULL) 
#alogliptin <- capture.output(PhViD.search(gps, DRUG = "ALOGLIPTIN", EVENT = NULL)) 
#cat("Alogliptin Signals" , alogliptin, file = "alogliptin.csv", sep = ",", append = TRUE) 
 
# where RESULT is the name of the results file 
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